WO2004016576A1 - 縮合ベンゼン誘導体および用途 - Google Patents
縮合ベンゼン誘導体および用途 Download PDFInfo
- Publication number
- WO2004016576A1 WO2004016576A1 PCT/JP2003/010228 JP0310228W WO2004016576A1 WO 2004016576 A1 WO2004016576 A1 WO 2004016576A1 JP 0310228 W JP0310228 W JP 0310228W WO 2004016576 A1 WO2004016576 A1 WO 2004016576A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- optionally substituted
- substituted
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/52—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of six-membered aromatic rings being part of condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/48—Halogenated derivatives
- C07C35/52—Alcohols with a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Definitions
- the present invention relates to a condensed benzene derivative useful as an androgen receptor module and a method for producing the same.
- Androgens are synthesized in the testis and adrenal cortex, bind to androgen receptors in target organs, and exert various biological activities. All natural androgens chemically belong to the C19 steroid. The major androgen is testosterone, which is synthesized mainly in the testis, and has strong uptake into target cells and bioactivity. In women, the adrenal cortex is the major source of androgens.
- Androgens maintain reproductive organs (prostate, seminal vesicles, epididymis, vas deferens, etc.), maintain sexual function, fetal sexual differentiation, spermatogenesis, and manifest secondary sex features (musculoskeletal, vocal, fat distribution, etc. ), The action of promoting protein assimilation in muscles, etc., and the effect on bone metabolism. Therefore, if androgen deficiency is caused by testicular dysfunction or castration, such effects become insufficient, leading to various diseases and a decrease in quality of life (QOL). This is usually treated with androgen replacement. In addition to testosterone, synthetic androgens with a different balance of androgen action have been studied and used clinically.
- testosterone and synthetic androgens are usually used. However, they have a steroid skeleton, which may place a heavy burden on the liver and may exhibit other steroid hormone effects. Therefore, the non-steroidal androgen receptor androgen receptor (especially agonists) improve the pathogenesis deficient in androgen action (hypogonadism, male menopause, etc.) and the effects of androgen. It is considered to be useful for conditions that can be expected to improve (eg, osteoporosis). 2 In addition, the present inventors have examined that when testosterone is reduced by castration or administration of GnRH agonist, some cancers acquire the ability to proliferate even with such low testosterone. It has been shown to exhibit antitumor effects.
- an object of the present invention is to provide an androgen receptor module (particularly agonist) having a nonsteroidal skeleton and to solve these problems.
- the present inventors have conducted intensive studies in view of the above circumstances, and as a result, have found that the compound represented by the general formula (I) has an excellent action as an androgen receptor module, The inventors have found what can be achieved, and have completed the present invention.
- ring A is a 5- to 8-membered ring which may be substituted
- ring B is a 4- to 10-membered ring which may be further substituted
- ring C is a benzene ring which may be further substituted.
- X 1 represents an optionally substituted carbon atom
- X 2 represents an optionally substituted carbon atom, an oxygen atom or a formula S (0) k (where k represents 0, 1 or 2). ) Represents a group represented by, respectively.
- W is a nitrogen atom, or a benzene ring which may be ring A is substituted, wherein CR a (wherein, R a represents a bond, a hydrogen atom, a hydroxyl group or an optionally substituted alkoxy group The group represented by) is shown.
- Y 11 is a group represented by the formula CR3 ⁇ 4 3 ′ (wherein, R 2 is a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an esterified or amidated carboxyl group, or an optionally substituted carboxyl group.
- a good hydrocarbon group may be a bond, a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated propyloxyl group, or an optionally substituted Represents a hydrocarbon group, and represents a group represented by).
- CR 5 ′ (wherein, R 4 is a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated propyloxyl group or a substituted R 5 ′ is a bond, a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an esterified or amidated lipoxyl group or a substituted hydrocarbon group.
- ring A is an optionally substituted benzene ring
- R 1 is a nitro group or an optionally substituted sulfamoyl group
- W is a nitrogen atom
- ring B is octahydro [1,2-a A pyrazine ring, a homopiperazine ring in which a nitrogen atom may be substituted with an alkyl group, or a 2,5,1-diazabicyclic mouth in which a nitrogen atom may be substituted with an alkyl group [2,2,1] heptane ring ,
- ring A is a furan ring or a pyran ring which may be substituted or saturated
- R 1 is a halogen atom
- W is a nitrogen atom
- ring B is substituted at the 3-position.
- a pyrrolidine ring substituted with a diamino group
- W is a group represented by the formula CR a (the symbols in the formula are the same as defined above), and the optionally substituted piperidine ring in which the ring B is bonded to the ring C at the 4-position; An optionally substituted 1, 2, 5, 6-tetrahydropyridine ring bonded to the C ring at the 4-position; and
- ring A is a 5- to 8-membered ring which may be substituted
- ring B is a 4- to 10-membered ring which may be further substituted
- ring C is a benzene ring which may be further substituted.
- X 1 represents an optionally substituted carbon atom
- X 2 represents an optionally substituted carbon atom, an oxygen atom or a formula S (0) k (where k represents 0, 1 or 2). ) Represents a group represented by, respectively.
- Y 1 is a group represented by the formula CR 2 R 3 (wherein R 2 and R 3 are the same or different and each may be a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an esterified or amidated
- Y 2 represents a group represented by the formula: CR 4 R 5 (wherein and R 5 are the same or different and represent a hydrogen atom, a cyano group, , A nitro group, an optionally substituted acyl group, a carboxyl group which may be esterified or amidated, or a hydrocarbon group which may be substituted.) Or a nitrogen atom, an oxygen atom or a group represented by the formula S (0) m (where m represents 0, 1 or 2), and the ring B may be further substituted.
- ring A is an optionally substituted benzene ring
- R 1 is a nitro group or an optionally substituted sulfamoyl group
- ring B is an octahydro [1,2-a] pyrazine ring
- a nitrogen atom is 2,5-Diazabicyclo [2,2,1] heptane in which a homopyrazine ring or a nitrogen atom optionally substituted with an alkyl group may be substituted with an alkyl group T / JP2003 / 010228
- Ring A is a furan or pyran ring which may be substituted or saturated, R 1 is a halogen atom, and ring B is substituted with an amino group which may be substituted at the 3-position.
- R 1 is a halogen atom
- ring B is substituted with an amino group which may be substituted at the 3-position.
- ring B optionally substituted pyrrolidine ring, optionally substituted piberidine ring, optionally substituted morpholine ring, optionally substituted thiomorpholine ring, optionally substituted Pyrazoline ring, optionally substituted birazolidine ring, optionally substituted isoxazoline ring, optionally substituted cyclopentane ring, optionally substituted cyclopentene ring or optionally substituted pyridine
- the compound of the above-mentioned [1] which is a loazepine ring;
- R 1 is Shiano group, a nitro group, a halogen atom, a substituted optionally may be Ashiru group, to be a carboxyl group or 1 may be esterified or amidated substituted with five halogen atoms d_ 6
- Substituents other than R a , R 2 , R 3 ′, R 4 and R 5 ′ on the A ring or the B ring are (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) nitro group, (5) hydroxyl group, (6) optionally substituted amino group, (7) optionally carboxyl group which may be esterified or amidated, (8) optionally substituted ( ⁇ 6 alkyl group, (9) an optionally substituted "6 Ashiru group, (10) an optionally substituted ( ⁇ _ 6 alkoxy group, (1 1) R 6 S (0) p (wherein And R 6 represents an alkyl group which may be substituted, and p represents 0, 1 or 2.), a oxo group, (13) a hydroxyimino group, and (14) a substituted [1]
- the above-mentioned [1] which is one or six groups selected from the group consisting of a 6 alkoxyimino group and a (15)
- R 7 is substituted by a cyano group, a nitro group, a halogen atom, an optionally substituted acyl group, an optionally esterified or amidated carbonyl group, or 1 to 5 halogen atoms the _ 6 alkyl group, R 8 and R 9 are identical or different dates (1) hydrogen atom, (2) Shiano group, (3) nitro group, (4) a halogen atom, with hydroxyl group or (6 alkoxy group ( 6 alkyl group, (5) halogen atom, hydroxyl group or alkoxy group, _ 6 acyl group,
- halogen atom a hydroxyl group or (6 alkoxy group optionally substituted - 6 alkoxy group or (7) an optionally esterified or amidated which may be a carboxyl group, q and is 0, 1 or 2 , Z 1 is carboxy group, hydroxy I amino group properly is substituted with an optionally substituted (6 Arukokishiimino group carbon atom, C M Al Kirenjiokishi carbon atoms or formula which is substituted with a group
- R 1Q and R 11 are the same or different and are (1) hydrogen atom, (2) halogen atom, (3) cyano group, (4) nitro group, (5) hydroxyl group, (6) halogen atom, hydroxyl group also properly C, - 6 alkoxy alkyl group which may be substituted with a group, (7) a halogen atom, may be substituted by hydroxyl or ( ⁇ _ 6 alkoxy group - 6 Ashiru group,
- Z 2 represents an oxygen atom, a sulfur atom, S0, S0 2
- Karuponiru group, hydroxy I amino group or a substituted is 6 may be alkoxy Kishiimino carbon atoms substituted with a group, an alkyl group or Ashiru amino group which may be substituted with a group, - 4 the carbon atoms are substituted with alkylenedioxy O alkoxy group Is the expression
- R 12 and R 13 are the same or different and are (I) hydrogen atom, (2) halogen atom, (3) cyano group, (4) nitro group, (5) hydroxyl group, (6) halogen atom, hydroxyl group also properly it is (6 alkoxy group substituted by 6 may be an alkyl group, (7) a halogen atom, a hydroxyl group or (_ 6 alkoxy group substituted by _ 6 may Ashiru group,
- X 3 represents a sulfur atom or an oxygen atom
- R 7 represents a cyano group, a dinitro group, a halogen atom, an optionally substituted acyl group, an esterified or amidated lipoxyl group Or an alkyl group substituted with 1 to 5 halogen atoms, wherein R 8 and R 9 are the same or different, and (1) a hydrogen atom, (2) a cyano group, (3) a nitro group, (4) a halogen atom , A 6- alkyl group which may be substituted with a hydroxyl group or an alkoxy group, (5) a halogen group, an acryl group which may be substituted with a hydroxyl group or an alkoxy group, and (6) a halogen atom, a hydroxyl group or an alkoxy group. optionally substituted C, - 6 alkoxy or (7) esterified verses JP2003 / 010228
- Z 1 is a carbonyl group, a hydroxyimino group or an optionally substituted ( ⁇ 6 alkoxyimino group, carbon atoms, C, _ 4 alkylenedioxy O carboxymethyl carbon atoms or substituted with a group of the formula
- R 1 "and R 11 are the same or different and are (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group, (5) a hydroxyl group, (6) a halogen atom, hydroxy group properly is optionally substituted alkyl group with an alkoxy group, (7) a halogen atom, a hydroxyl group or _ 6 alkoxy-substituted _ 6 may Ashiru group group, (8) a halogen atom, a hydroxyl group or _ 6 alkoxy group optionally substituted 6 alkoxy group, (9) alkyl group and / or Moyoi substituted with Ashiru group Amino group or (1 0) esterified or amidated unprotected Cal a group represented by the Pokishiru group respectively.), Z 2 represents an oxygen atom, a sulfur atom, S0, S0 2, force Ruponiru group, substituted with hydroxy I amino group or an
- R 12 and R 13 are the same or different and are (1) hydrogen atom, (2) halogen atom, (3) cyano group, (4) nitro group, (5) hydroxyl group, (6) halogen atom, hydroxyl group also is properly Ci_ may be substituted with 6 alkoxy group CI- 6 alkyl group, (7) a halogen atom, a hydroxyl group or an optionally substituted Ashiru group an alkoxy group,
- X 3 is an oxygen atom
- R 7 is a halogen atom
- Q is 0,
- R 8 and R 9 are hydrogen Is an atom:
- Z 1 is the formula
- R 1 ′′ and R 11 represents a hydrogen atom, and the other represents an amino group which may be substituted by a 6 alkyl group and / or a 6 acyl group.
- Z 2 is a methylene group
- ring A a is a 5- to 8-membered ring which may be substituted, ring C a may be further substituted. Listen to PC 10228
- x la is an optionally substituted carbon atom
- x 2a is an optionally substituted carbon atom
- R la represents an electron-withdrawing group
- M represents a leaving group.
- ring Ba represents a 4- to 10-membered ring which may be further substituted.
- Y la is a group of the formula CR 3a (wherein R 2a and R 3a are the same or different and are a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an esterified or amidated force ropoxyl
- Y 2a is a group represented by the formula CR 4a R 5a (wherein R 4a and R 5a are the same or different and each represents a hydrogen atom, a cyano group or a hydrocarbon group which may be substituted).
- ring ⁇ is an optionally substituted 5- to 8-membered ring
- ring B is an optionally substituted 4- to 10-membered ring
- ring C is an optionally substituted benzene ring
- X 1 represents an optionally substituted carbon atom
- X 2 represents an optionally substituted carbon atom, an oxygen atom or a formula S (0) k (where k represents 0, 1 or 2).
- W 1 represents a nitrogen atom or a group represented by the formula CR a (wherein, Ra represents a bond, a hydrogen atom, a hydroxyl group or an optionally substituted alkoxy group).
- Y 11 is a group represented by the formula CR 3 ′ (wherein R 2 is a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated propyloxyl group or a substituted R 3 ′ is a bond, a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an esterified or amidified carboxyl group or a substituted hydrocarbon group.
- R 5 ′ is a bond, a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, or an optionally amidated hydroxyl group or an optionally substituted hydrogen group; , Esterification or Shows the imidization which may force even if Rupokishiru group or an optionally substituted hydrocarbon group, respectively.
- Ru group an optionally substituted nitrogen atom, an oxygen atom or a group represented by formula S (0) m ( In the formula, m represents 0, 1 or 2.
- R 1 represents an electron-withdrawing group.
- the formula represents a single bond or a double bond.
- a prophylactic / therapeutic agent for osteoporosis comprising the modulator of the above-mentioned [15];
- a prophylactic or therapeutic agent for hormone-resistant cancer comprising an androgen receptor agonist
- LH-RH module is an LH-RH agonist.
- a method for preventing or treating cancer which comprises administering to a mammal an effective amount of the compound according to [1], a salt thereof, or a drug therefrom;
- a method for preventing and treating cancer comprising administering to a mammal a combination of an effective amount of the compound according to [1] or a salt thereof or a prodrug thereof and an effective amount of a hormonal therapeutic agent. ;
- a method for preventing or treating cancer which comprises administering an effective amount of the compound according to the above [1], a salt thereof, or a free drug thereof after administration of another anticancer agent;
- a method for preventing and treating cancer which comprises administering an effective amount of a prodrug;
- a method for preventing or treating cancer which comprises administering an effective amount of a drug;
- a medicine comprising a combination of the agent according to the above [13] and an anticancer agent;
- a method for preventing and treating cancer which comprises administering an effective amount of the agent according to [13] to a mammal;
- a method for preventing and treating cancer which comprises administering to a mammal a combination of an effective amount of the agent described in [13] and an effective amount of another anticancer agent;
- a method for preventing and treating cancer which comprises administering to a mammal a combination of an effective amount of the agent described in the above [13] and an effective amount of a hormonal therapy agent;
- Ring A is an optionally substituted benzene ring
- Ring B a piperidine ring optionally substituted,
- Optionally substituted pyrazine optionally substituted morpholine ring, optionally substituted thiomorpholine ring or optionally substituted perhydro PC orchid painting 10228
- the present invention relates to the medicament according to the above [12], which is an agent for preventing or treating hormone-resistant cancer.
- the contents of the present invention will be described in detail.
- R 2 , R 2a , R 3 , R 3 ′, R 3a , R 4 , R 4a , R 5 , R 5 ′ and R 5a examples include “aliphatic hydrocarbon group”, “alicyclic hydrocarbon group” and “aromatic hydrocarbon group”.
- aliphatic hydrocarbon group as an example of the hydrocarbon group, a linear or branched aliphatic hydrocarbon group such as an alkyl group, an alkenyl group and an alkynyl group is used.
- alkyl group includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and isohexyl.
- alkyl group such as 1-, 1-methylheptyl, nonyl and the like can be used, but preferably (: alkyl (eg, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl) Butyl, etc.) can be used.
- alkenyl group examples include bier, aryl, isoprobenyl, 2-methylaryl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2- Ethyl 1-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl C 2 ⁇ Q alkenyl groups such as, 3-hexenyl, 4-hexenyl, 5-hexenyl Which can be used.
- it is a C 2 _ 6 alkenyl group.
- Alkynyl groups include, for example, ethel, 1-propynyl, 2-propenyl, 1-butynyl, 2-butynyl, 3-buteryl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2 C 2 _ 1 () alkynyl groups such as —hexynyl, 3-hexynyl, 4-hexynyl, and 5-hexynyl are used. Preferred is a C 2 _ 6 alkynyl group.
- alicyclic hydrocarbon group as examples of the hydrocarbon group, for example, a cycloalkyl group, cycloalkenyl group, cycloalkane Genis Le groups and these with C 6 _ 14 Ari Le group (e.g., benzene etc.) and the like
- C 6 _ 14 Ari Le group e.g., benzene etc.
- a saturated or unsaturated, monocyclic or condensed polycyclic, alicyclic hydrocarbon group such as a bicyclic or tricyclic condensed ring is used.
- cycloalkyl group for example, cyclopropyl, cyclobutyl, consequent opening pentyl, cyclohexyl, cycloheptyl cyclohexane, Shikurookuchiru, cyclononyl of which C 3 - like i 0 consequent opening alkyl is used.
- cycloalkenyl group examples include, for example, 2-cyclopentene-11-yl, 3-cyclopentene-11-yl, 2-cyclohexene-11-yl, 3-cyclohexene-11-yl And ⁇ 3 _ 1 () cycloalkenyl groups such as benzyl, 1-cyclobutene-11-yl and 1-cyclopentene-11-yl.
- cycloalkenyl group examples include, for example, C 4 such as 2,4-cyclopentene-1-yl, 2,4-cyclohexadiene-l-yl, and 2,5-cyclohexan-gen-1-yl — A 6- cycloalkaneenyl group is used.
- aromatic hydrocarbon group a monocyclic or condensed polycyclic aromatic hydrocarbon group is used is not particularly limited, preferably C 6 _ 2 2 Aromatic carbonization hydrogen group, and more preferably 8 aromatic hydrocarbon group, more preferably C 6 -, etc. 1 0 Kaoru aromatic hydrocarbon group.
- the term “electron-withdrawing group” represented by KR la generally refers to a group that has a tendency to attract electrons from others when hydrogen is used as a standard in the molecule, and is not particularly limited as long as it is used in organic chemistry.
- a cyano group, a nitro group, a halogen atom, an optionally substituted acyl group, a carboxyl group which may be esterified or amidated, or ( 6- alkyl substituted with 1 to 5 halogen atoms A group or the like can be used.
- R 6 and "ring A or on B ring on R a, R 2, R 3 ', and R 5' substituent other than""_ 6 in” substituted 6 may be alkyl, "as shown in As the “alkyl group”, the same as defined above is used. ,
- a ring or on the B ring on R a, R 2, R 3 ', and R 5' non-substituent" in the "in” replacement is also be _ 6 alkoxy group optionally "(S alkoxy group represented Examples of "" include methoxy, ethoxy, n-propoxy, isopropyloxy, n-butoxy, isobutyloxy, sec-butyloxy, tert-butyloxy, n_pentyloxy, isopentyloxy, neopentyloxy, n —Hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy, 2-ethylbutyloxy and the like can be used.
- Preferred are methoxy, ethoxy, n-propoxy, isopropyloxy, n-butoxy and the like.
- alkoxy group of the "optionally substituted alkoxy group” represented by R a preferably is _ 6 alkoxy groups such as methoxy, ethoxy, n- Provo alkoxy, isopropyl O alkoxy, n- Bed Bok alkoxy, Isobutyloxy, sec-butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy Xy, 3,3-dimethylbutyloxy, 2-ethylbutyloxy and the like can be used.
- Preferred are methoxy, ethoxy, n-propoxy, isopropyloxy, n-butoxy and the like.
- halogen atom is a fluorine atom, a chlorine atom, A bromine atom or an iodine atom can be used. Preferably it is a fluorine atom or a chlorine atom.
- acyl group in the “acyl group” include, for example, lower (C n) alkanoyl groups such as formyl, acetyl, propionyl, butyryl, isoptyryl, valeryl, isovaleryl, pivaloyl, and hexanoyl; acryloyl, methacryloyl, crotonyl lower (C 3 one 7) Arukenoi Le group and the like; cyclopropane Cal Poni group, cyclobutane Cal Poni group, cyclopentanecarbonitrile cycloalkenyl group, C 4 _ 7 cycloalkane carbonylation Le groups such as hexane carbonyl cyclohexane; mesyl group and the like.
- Akuriroiru, main Takuriroiru, Kurotonoiru, Isokurotonoiru such as lower (C 3 one 6) Alkenol group; C 4 _ 6 cycloalkanecarbonyl group such as cyclopropane carbonyl group, cyclobutane carbonyl group and cyclopentane carbonyl group can be used.
- R ⁇ R la R 2, R 2a, R 3, R 3 ', R 3a, R 4, R 4a, R 5, R 5', R 5a, R 7, R 8, R 9, R 10, R u , R t2 , R 13 and ⁇ esterified or amidated '' represented by the substituents other than R a , R 2 , R 3 ′, R 4 and R 5 ′ on ring A or ring B.
- the “good carboxyl group” include alkoxyl group, alkoxyl alkenyl, aryloxycarbonyl, aralkyloxyl propylonyl, ylbamoyl, N-monosubstituted carpamoyl and ⁇ , ⁇ -diamine.
- a substituted carbamoyl or the like can be used.
- alkoxycarbonyl includes, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, phenylcarbonyl Seo pliers Ruo alkoxycarbonyl, lower, such as neopentyl O butoxycarbonyl ( ⁇ - 6) alkoxycarbonyl two Le etc. of des be used, inter alia methoxy Cal Poni Le, E Bok Kishikaruponiru, such as propoxy force Ruponiru - 3 alkoxy cull Poni Le etc.
- the “lower alkoxycarbonyl” may have a substituent, and the substituent may be a hydroxyl group, an optionally substituted amino group [The amino group may be, for example, 1 to 5 halogen atoms (for example, fluorine , Chlorine, bromine, iodine, etc., and lower alkyl groups (eg, methyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.), and the like.
- halogen atoms for example, fluorine , Chlorine, bromine, iodine, etc.
- lower alkyl groups eg, methyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.
- a halogen atom eg, fluorine, chlorine, bromine, iodine, etc.
- a nitro group e.g., a cyano group
- a lower alkoxy group optionally substituted with 1 to 5 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.)
- Ci- 6 alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc., preferably methoxy, ethoxy, etc.
- these substituents are preferably substituted with 1 or 2 or 3 (preferably 1 or 2) identically or differently.
- aryloxycarbonyl includes, for example, phenoxyl
- aryloxycarbonyl and the like such as 1-naphthoxycarbonyl, 2-naphthoxycarbonyl and 1-phenanthoxycarbonyl.
- the “aryloxycarbonyl” may have a substituent, and the same substituent having the same number and the same as the substituent in the “alkoxycarbonyl” as the above substituent is used. Can be.
- aralkyloxypropyl is, for example, benzyloxycarbo. Cycloalkenyl, Hue phenethyl Ruo carboxymethyl cull Poni Le like C 7 _ i 4 Ararukiruokishi force Ruponiru etc. (good Mashiku is. Ariru one C i-4 alkoxy Ichiriki Ruponiru etc.) are preferable.
- the “aralkyloxycarbonyl” may have a substituent, and the same substituent having the same number and the same as the substituent in the “alkoxycarbonyl” as the substituent is used. be able to.
- N-monosubstituted rubamoyl includes, for example, lower alkyl (eg, alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.), lower alkenyl (eg, vinyl, Ariru, isopropenyl, Purobe sulfonyl, butenyl, pentenyl, to such C 2 _ 6 an alkenyl such as cyclohexenyl), cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl Le, the cyclohexyl and the like cyclohexane C 3 - 6 cycloalkyl, etc.), Ariru (e.g., phenyl, 1 one-naphthyl, 2-C 6 4 0 Ariru etc.
- Ararukiru e.g., benzyl, C 7 such as phenethyl - 1 Q Ararukiru, preferably phenyl - C ⁇ - 4 alkyl and the like
- ⁇ reel alkenyl e.g., C 8 of cinnamyl etc. - 1 () Arirua Kenyir, preferably phenylene Lou C 2 - 4 alkenyl and the like), those similar to the "heterocyclic group" of the "optionally substituted heterocyclic group” as the Hajime Tamaki (e.g., below substituent group), etc. Can be used.
- the lower alkyl, lower alkenyl, cycloalkyl, aryl, aralkyl, arylalkenyl, and heterocyclic group may have a substituent, and the substituent may be, for example, the “alkoxy force” as the substituent described above. And the same number of the same substituents as in the “luponyl” can be used.
- N, N-disubstituent rubamoyl means a diluvamoyl group having two substituents on a nitrogen atom, and one example of the substituent is “N—N-disubstituent rubamoyl”.
- the same substituents as those in "monosubstituted rubamoyl" can be used.
- lower alkyl eg, methyl, ether, propyl, isopyl, butyl, tert-butyl, pentyl, hexyl
- C 3 - - equal 7 cycloalkyl e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like to the consequent opening
- Ararukiru e.g., benzyl, phenethyl, etc., preferably phenyl - alkyl Etc.
- Nocarbamoyl includes, for example, 1-azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, piperidinocarbonyl, morpholino-capillonyl, 1-piperazinylcarbonyl and lower alkyl at the 4-position (eg, methyl, ethyl, propyl, isopropyl, butyl) , tert- butyl, pentyl, 6 alkyl or the like hexyl, etc.), Araru kill (e.g., benzyl, C 7 _ i 0 Ararukiru etc.
- Ariru eg, full Eniru, 1 one-naphthyl, 2 _ naphthyl
- a 3- to 8-membered (preferably 5- to 6-membered) cyclic amino group such as 1-piperazinylcarbonyl, which may have C 6 — 1 () aryl, etc.
- 1-piperazinylcarbonyl which may have C 6 — 1 () aryl, etc.
- halogen atoms represented by RR la and R 7 , 1 to 5, preferably 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, optionally C, _ 6 alkyl (eg have a iodine), methylation, Echiru, propyl, isopropyl, butyl, isobutyl, sec- butyl, ter t-butyl, pentyl, hexyl etc.) and the like to Specific examples thereof include, for example, fluoromethyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, 1-fluoroethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, pennofluorethyl, 2-fluoropropyl, 1-fluoroethyl, , 2-Difluoropropyl, 3,3,3-Trifluoroprop
- C W alkylenedioxy group in “( 4 carbon atom substituted by alkylenedioxy group)” represented by Z 1 and Z 2 , and “R a , R 2 on ring A or ring B”
- (w alkylenedioxy group” in the “optionally substituted ( 4 alkylenedioxy group)” represented by “substituents other than R, 3 ′, R 4 and R 5 ′”
- (w alkylenedioxy group” includes, for example, a methylenedioxy group Examples thereof include an ethylenedioxy group, a propylenedioxy group, a petylenedioxy group, etc. Preferred are a methylenedioxy group and an ethylenedioxy group.
- methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl can be used.
- hexyl iso, 1, -1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 3, 3 _ dimethylpropyl, 2-E Chirubuchiru, substitutable positions (6 alkyl group such as n- heptyl To 0 5, preferably 0 to 3, fluorine, chlorine, bromine, iodine; hydroxyl; methoxy, ethoxy, n-propoxy, isopropyloxy, n-butoxy, isobutyloxy, sec— Butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3, 3 - dimethyl-butyl O carboxymethyl, 2-E chill Petit Ruo alkoxy such as -.
- R 8, R g, R 10 , R “, R 12, R 13, in denoted as” a halogen atom, a hydroxyl group or _ 6 alkoxy which may be substituted Ci_ have 6 Ashiru group group "defined above substituted by "C, _ 6 ⁇ Shi Le group” 0 to 5 at substitutable positions, preferably three to 0, "halogen atom” defined above, a hydroxyl group, '_ 6 alkoxy group "defined above Those that have been used can be used.
- R 8 , R 9 , R 10 , R u , R 12 , R 13 represented by the ⁇ (halogen atom, hydroxyl group or (alkoxy group optionally substituted by 6 alkoxy group) '' as defined above ⁇ ( ⁇ 6 alkoxy group '' is substituted with 0 to 5, preferably 0 to 3, substituted with a ⁇ halogen atom '', a hydroxyl group or a ⁇ ( 6 alkoxy group '' as defined above.
- R 10, as R 11, R 12 and "_ 6 alkyl groups and / or (6 Ashiru amino group which may be substituted with a group" represented by R 13 are the Amino group, methyl, Edjiru, flop port pill D- 6 alkyl groups such as isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl, and formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, acryloyl, mechacryloyl can Kurotonoiru, Isokurotonoiru cyclopropane force Lupo two group, 0 to selected from C doctor 6 ⁇ sill group such as cyclobutane Cal Poni Le group and cyclopentane Cal Poni Le group be used which two groups are substituted.
- D- 6 alkyl groups such as isopropyl,
- an amino group includes methyl, ethyl, propyl, isopropyl, butyl, isoptyl, tert-butyl, C ⁇ of hexyl etc.
- pentyl and to - those 6 0 to the two groups alkyl group or al selected is substituted or formyl, Asechiru, propylidene Oxygen selected from the group consisting of carbonyl, octyl, butyryl, isoptyryl, valeryl, isovaleryl, piperyl, hexanoyl, acryloyl, methacryloyl, crotonyl, isocrotonyl, cyclopropanecarbonyl, cyclobutanecarbonyl and cyclopentane Can be used.
- propylidene Oxygen selected from the group consisting of carbonyl, octyl, butyryl, isoptyryl, valeryl, isovaleryl, piperyl, hexanoyl, acryloyl, methacryloyl, crotonyl, isocrotonyl, cyclopropanecarbonyl, cyclobutanecarbonyl and
- 8-membered ring of the "substituted 5- or may be 8-membered ring” represented by ring A and A a ring, for example, “alicyclic hydrocarbon”, “aromatic hydrocarbon”, " And the like.
- alicyclic hydrocarbon for example, a saturated or unsaturated, monocyclic or fused polycyclic, such as cycloalkane, cycloalkene, cycloalkanegen and a bicyclic fused ring thereof and benzene, 5 _ 8 or C 4 i. Alicyclic hydrocarbons are used.
- cycloalkane for example cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, etc.
- C 3 _ 10 cycloalkanes such cyclononane is used.
- cycloalkene for example cyclopentene, cyclohexene, C 3 _ i, such Sik Robuten. Cycloalkene and the like are used.
- cycloalkane Zhen for example consequent opening pen evening Zhen, hexa cyclohexane Zhen, such as the Ru used C 4 6 cycloalkane Gen such Kisanjen cyclohexylene.
- aromatic hydrocarbon a monocyclic or condensed polycyclic aromatic hydrocarbon is used, is not particularly limited, preferably C 6 _ 8 aromatic hydrocarbon, more preferably C 6 aromatic hydrocarbon And so on.
- benzene, toluene, xylene, mesitylene, cumene, styrene, 1,2,3-trimethylbenzene, pentylene, and the like are preferable, and benzene, toluene and the like are preferably used.
- heterocycle includes, for example, at least one to three (preferably one or two) heteroatoms selected from oxygen, sulfur, and nitrogen as atoms constituting a ring system (ring atoms).
- An aromatic heterocyclic ring containing 1 (preferably 1 to 4, more preferably 1 or 2), a saturated or unsaturated non-aromatic heterocyclic ring (aliphatic heterocyclic ring) and the like are used, but are not particularly limited. And preferably a 4- to 10-membered or 5- to 8-membered heterocycle.
- aromatic heterocycle examples include a 5- to 10-membered aromatic heterocycle, for example, a 5- or 6-membered aromatic monocyclic heterocycle (eg, furan, thiophene, pyrrole, oxazole, isoxazole) , Thiazole, isothiazole, imidazole, pyrazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazol, furazan, 1,2,3-thiadiazol, 1 , 2,4-thiaziazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1, Z, 4-triazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine ), And 8- to 10-membered aromatic condensed heterocycles (eg, 1 / J-pyrro [1,2-c] imidazole, pyro [1,2-a] imidazole, pyro [
- non-aromatic heterocycle include, for example, oxetane, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, quinuclidine, aziridine, oxolane, azetidine, pyrrolidine, tetrahydrofuran, thiolane, piperidine, tetrahydropyran, Dioxolane, thiazane, morpholine, thiomophoroline, piperazine, azepan, perhydroindole, perhydropyro [2,3-d] pyridine, perhydropyro [3,2-d] pyridine, 7-azabicyclo [2,2,1] ] A 4- to 10- or 5- to 8-membered saturated or unsaturated (preferably saturated) non-aromatic heterocycle (aliphatic) such as heptane, or a compound in which part or all of the above aromatic heterocycle is saturated Heterocycle
- CR 2 in Y 1 or CR 4 or a nitrogen atom in may form a part of the ring B.
- CR 4a or the nitrogen atom in the CR 2a or Y 2a in Y la may constitute a part of the B a ring.
- CR 2 in Y 11 or CR 4 or a nitrogen atom in Y 21 may form a part of the ring B.
- a "further is substituted represented by the ring B and B a ring; substituents of the" no .5 optionally substituted 8-membered ring "for ring and A a ring It is "substituted A-ring; substituents in even benzene ring” substituted by "is found represented by C ring and C a ring: the substituents in which 4 to 10 membered ring may have” A substituent in the "good benzene ring”;”optionally substituted pyrrolidine ring", “optionally substituted piperidine ring”, “optionally substituted piperazine ring”, “substituted”
- the substituent in the present invention such as a substituent in the ⁇ optionally substituted morph
- alkyl group in the “optionally substituted alkyl group” as the substituent examples include methyl, ethyl, n-propyl, isopropyl, n-butyl and iso-alkyl.
- a lower alkoxy group e.g., methoxy, ethoxy, C ⁇ propoxy etc. - 6 alkoxy and the like
- a halogen atom e.g., fluorine, chlorine, bromine, iodine
- lower alkyl group e.g, methylation, Echiru, alkyl of propyl, etc.
- lower alkenyl groups e.g., vinyl, C etc.
- Optionally substituted amino group “optionally substituted hydroxyl group”, and “optionally substituted amidino group” as substituents of the above-mentioned “optionally substituted alkyl group” are ⁇ optionally substituted amino group '', ⁇ optionally substituted hydroxyl group '', and ⁇ optionally substituted The same as those described for the “amidino group” can be used.
- alkenyl group in the “optionally substituted alkenyl group” as the substituent examples include, for example, bier, aryl, isopropenyl, 2-methylaryl, 1-propyl, 2-methyl- 1-propyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1butenyl, 2-methyl-2-butenyl, 3-methyl-2- Butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, etc.
- C 2 - 6 alkenyl or the like can be used.
- substituent of the alkenyl the same number of the same substituents as the substituent in the “optionally substituted alkyl group” as the substituent can be used.
- alkynyl group in the “optionally substituted alkynyl group” as the substituent include, for example, ethynyl, 1-propynyl, 2-propiel, 1-butyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl , 3 - pentynyl, 4 one pentynyl, 1 one to hexynyl, 2 into single hexynyl, 3 one to hexynyl, carboxymethyl sulfonyl into 4 one, C 2 of Kisheru like to 5 - can be used 6 alkynyl.
- substituent of the alkynyl group the same
- Ariru group in the "optionally substituted Ariru group” as a substituent can be for example phenyl, naphthyl, anthryl, Fuenantoriru, be used (6 _ 1 4 Ariru such as Asenafuchire nil.
- substituent of the aryl group the same number of the same substituents as those in the “optionally substituted alkyl group” as the substituent can be used.
- aralkyl group in the “optionally substituted aralkyl group” as the substituent for example, C 7 -aralkyl such as benzyl, phenethyl and naphthylmethyl can be used.
- substituent of the aralkyl group the same number of the same substituent as the substituent in the “optionally substituted alkyl group” as the above-mentioned substituent can be used.
- the cycloalkyl group in the "optionally substituted cycloalkyl group" as the substituent such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl cyclo, C 3 of heptyl and the like cyclohexane - using 7 cycloalkyl such as be able to.
- substituent of the cycloalkyl group the same number of the same substituents as in the above-mentioned “optionally substituted alkyl group” as the substituent can be used.
- the Roarukeniru groups such Shikuropuro base sulfonyl, cyclobutenyl, Shikuropen thenyl, C 3 of cyclohexenyl, etc., to a consequent opening - 7 Shikuroaruke two Le like can be used.
- the substituent of the optionally substituted cycloalkenyl group the same number of the same substituents as those in the above-mentioned ⁇ optionally substituted alkyl group '' as the substituent may be used. Can be.
- heterocyclic group in the “optionally substituted heterocyclic group” as the substituent for example, a heteroatom selected from an oxygen atom, a sulfur atom, a nitrogen atom and the like as an atom (ring atom) constituting a ring system
- An aromatic heterocyclic group containing at least 1 (preferably 1 to 4, more preferably 1 to 2) of 1 to 3 (preferably 1 to 2), a saturated or unsaturated non-aromatic heterocyclic group Groups (aliphatic heterocyclic groups) and the like can be used.
- the “aromatic heterocyclic group” includes, for example, furyl, chenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxazinediazol, 1,2,4-oxaziazolyl, 1,3,4-oxadiazolyl, furazanil, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl
- a 5- or 6-membered monocyclic aromatic heterocyclic group such as tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like, and, for example, benzofuranyl, isobenzofuranyl, benzo.C_b] chenyl, indo
- non-aromatic heterocyclic group includes, for example, 3 to 8 such as oxilanyl, azetidinyl, oxetanyl, cesinyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl, tetrahydrovinylanyl, morpholinyl, thiomorpholinyl, piperazinyl and the like.
- non-aromatic heterocyclic group aliphatic heterocyclic group or the like, or 1,2,3,4-tetrahydroquinolyl
- a ring group or the like can be used.
- alkyl group e.g., methyl, Echiru, propyl, etc. ( ⁇ _ 6 alkyl or the like
- a lower alkenyl group e.g., pinyl, C 2 etc. Ariru - 6 alkenyl, etc.
- lower Arukini Le group eg, Echiniru, c 2 _ 6 alkynyl, etc.
- the "optionally substituted heterocyclic group" as a substituent may have “optionally substituted amino group”, “optionally substituted hydroxyl group”, and “optionally substituted Examples of the "good imidoyl group” and the “optionally substituted amidino group” include a "optionally substituted amino group” as a substituent such as an "optionally substituted aromatic ring” described later; The same groups as the “optionally substituted hydroxyl group”, “optionally substituted imidyl group”, and “optionally substituted amidino group” can be used.
- substituents in the “hydroxyl group” and the “optionally substituted thiol group” include, but are not limited to, optionally halogenated C 6 alkoxy (eg, methoxy, ethoxy, trifluoromethoxy, 2, 2 , 2-Trifluoroethoxy, trichloromethoxy, 2,2,2-trichloroethoxy, etc.) and alkylaryl groups (eg, 0-toluyl, m-tolyl, P-tolyl, xylyl, mesityl, etc., preferably (: Bok 5 alkyl - substituted lower alkyl group (e.g.
- acyl group C ⁇ 6 alkanol (eg, formyl, acetyl, propionyl, vivaloyl, etc.) Alkyl, sulfonyl (eg, methanesulfonyl, etc.), benzenesulfonyl, etc., optionally halogenated alkoxyl group (eg, methoxycarbonyl, ethoxycarbonyl, trifluoromethoxycarbonyl, 2,2,2-) Trifluoroethoxycarbonyl, trichloromethoxycarbonyl, 2,2,2-trichloromethoxycarbonyl, etc.), an alkoxycarbonyl group (eg, benzyloxycarbonyl, etc.) which may be substituted by a phenyl group, example, phenyl, 1 one-naphthyl, 2-naphthyl C 6 _ 1 () Ariru
- reel alkenyl preferably instrument is off Et two Lou C 2 - 4 alkenyl and the like
- the substituent preferably pyridyl, even more preferably 4 Monopyridyl etc.
- One to three of these optional substituents may be substituted at substitutable positions.
- amino group in “optionally substituted amino group” as a substituent, an optionally substituted imidoyl group (e.g., ( ⁇ _ 6 alkyl imidoyl (eg, formyl imidoyl, ⁇ cetyl imidoyl etc.), alkoxy imides I le, - 6 alkyl thio imidoyl, amidino, etc.), 1-2 -. 6 alkyl amino group which may be substituted with group may be substituted for these One or two optional substituents may be substituted at substitutable positions, or two substituents may form a cyclic amino group together with a nitrogen atom.
- an optionally substituted imidoyl group e.g., ( ⁇ _ 6 alkyl imidoyl (eg, formyl imidoyl, ⁇ cetyl imidoyl etc.), alkoxy imides I le, - 6 alkyl thio imidoyl, amidino, etc.),
- Circular ring in case Examples of the amino group include 1-azetidinyl, 1-pyrrolidinyl, piperidino, thiomorpholino, morpholino, 1-piperazinyl and lower alkyl at the 4-position, (eg, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl). ( ⁇ _ 6 alkyl etc.), aralkyl (eg, benzyl, phenethyl, etc. C 7 _ 1 () aralkyl etc.), aryl (eg, phenyl, 1-naphthyl, 2-naphthyl, etc.
- C 6 _ 1 A 3- to 8-membered (preferably 5- to 6-membered) cyclic amino such as 1-piperazinyl, 1-pyrrolyl, 1-imidazolyl, etc. which may have a substituent.
- alkylsulfenyl group in the “optionally substituted alkylsulfinyl group” as the group include methylsulfinyl and ethylsulfinyl Cycloalkenyl, profile Pils sulfinyl, isopropyl-sulfinyl, butyl sulfide El, Isopuchi Rusurufiniru, sec- butylsulfinyl, tert- butylsulfinyl, pentyl sulfinyl, to a C 6 alkylsulfinyl such as hexyl sulfinyl can and Mochiiruko.
- Arukirusu ⁇ As the substituent for
- Examples of the “carboxyl group which may be esterified or amidated” as the substituent include carboxyl group, alkoxycarbonyl, aryloxycarbonyl, aralkyloxycarbonyl, carbamoyl, N-monosubstituted rubamoyl ⁇ and ⁇ , ⁇ -disubstituted Lubamoyl can be used.
- alkoxycarbonyl includes, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, isopentyl Okishikaruponiru, neopentyl O carboxymethyl C _ 6 alkoxy Cal Poni Le (lower alkoxycarbonyl two Le) or the like can be used, such as carbonyl, inter alia methoxy Cal Poni Le, ethoxy Cal Poni le, such as flop port Po alkoxycarbonyl ⁇ - g alkoxy cull Poni Le etc.
- the "lower alkoxycarbonyl” may have a substituent, and the substituent may be a hydroxyl group, an amino group which may be substituted [The amino group may be, for example, 1 to 5 halogen atoms. (For example, lower alkyl optionally substituted with fluorine, chlorine, bromine, iodine, etc.) Groups (eg, alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc., preferably methyl, ethyl, etc.), and acyl groups (eg, formyl, acetyl, propionyl, pivalyl, etc.) Bruno - 6 Arukanoiru, Benzoiru etc.), the force Rupokishiru group may have a one or two substituents such as alkoxy force Ruponiru.
- Halogen atom for example, fluorine, chlorine, bromine, iodine, etc.
- nitro group cyano group
- lower alkoxy which may be substituted with 1 to 5 halogen atoms (for example, fluorine, chlorine, bromine, iodine, etc.)
- Groups for example, alkoxy such as methoxy, ethoxy, n_propoxy, isopropoxy, n_butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like, preferably methoxy, ethoxy and the like
- substituents are preferably the same or different and are substituted with 1 or 2 to 3 (preferably 1 or 2) substituents.
- aryloxycarbonyl is preferably, for example, C 4 aryloxycarbonyl, such as phenoxycarbonyl, 1-naphthoxycarbonyl, 2-naphthoxycarbonyl, 1-phenanthoxycarbonyl, and the like.
- the “aryloxycarbonyl” may have a substituent, and the same substituent having the same number and the same as the substituent in the “alkoxycarbonyl” as the above substituent is used. Can be.
- Ararukiruokishi force Ruponiru is, for example, benzyl O carboxymethyl Cal Po sulfonyl, Hue phenethyl Ruo carboxymethyl C 7 _ 4 Ararukiruokishi force Ruponiru like (good Mashiku such carbonyl, C 6 -. I ⁇ Li one Roux alkoxy Ichiriki Luponyl and the like).
- the “aralkyloxycarbonyl” may have a substituent, and the same substituent having the same number as that of the above “alkoxycarbonyl” as the substituent can be used. .
- N-monosubstituted rubamoyl includes, for example, lower alkyl (eg, alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.), lower alkenyl ( examples include vinyl, Ariru, isoproterenol base alkenyl, propenyl, butenyl, C 2 _ 6 an alkenyl, etc.), cycloalkyl (example hexenyl, etc. pentenyl, to, cyclopropyl, cyclobutyl, cyclopentyl PT / JP2003 / 010228
- lower alkyl eg, alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl
- () ⁇ reel alkenyl, preferably phenylene Lou C 2 _ 4 alkenyl, etc.), complex A ring group (for example, the same as the “heterocyclic group” in the “optionally substituted heterocyclic group” as the substituent) and the like can be used.
- the lower alkyl, lower alkenyl, cycloalkyl, aralkyl, aralkyl, arylalkenyl, and heterocyclic group may have a substituent, and the substituent may be, for example, the “alkoxy force” as the substituent described above. And the same number of the same substituents as in the “luponyl” can be used.
- N, N-disubstituent rubamoyl means a diluvamoyl group having two substituents on a nitrogen atom, and one example of the substituent is “N— The same substituents as those in "monosubstituted rubamoyl” can be used.
- lower alkyl eg, methyl, ether, propyl, isopyl, butyl, tert-butyl, pentyl, hexyl
- C 3 _ 7 cycloalkyl eg of equal, cyclopropyl, cyclobutyl, cyclohexyl, etc.
- Nocarbamoyl includes, for example, 1-azetidinyl carbonyl, 1-pyrrolidinyl carbonyl, piperidino carbonyl, morpholino carbonyl, 1-piperazinyl carbonyl and lower alkyl at the 4-position (eg, methyl, ethyl, propyl, isopropyl, C-alkyl such as butyl, tert-butyl, pentyl, hexyl, etc., aralkyl (eg, benzyl, phenethyl, etc., aralkyl etc.), aryl (eg, phenyl, 1-naphthyl, 2-naphthyl, etc., C) 6 _ 1 0 ⁇ Li Ichiru etc.) and the like may have a 1-piperazinyl Luc
- substituent of the “optionally substituted thiocarbamoyl group” and the “optionally substituted sulfamoyl group” as the substituent include “e” as the substituent.
- substituents as the “N-monosubstituent rubamoyl” and the “N, N-disubstituent rubamoyl” in the “sterolized or amidated dextrin group” can be used.
- ⁇ sulfonic acid-derived acyl '' for example, those in which the above-mentioned ⁇ N-monosubstituent rubamoyl '' having one substituent on the nitrogen atom is bonded to sulfonyl can be used. preferably, methanesulfonyl, C 1 such Etansuru Honiru - it can be used 6 Ashiru such alkylsulfonyl.
- a hydrogen atom or a compound in which the above-mentioned “N-monosubstituent rubamoyl” has one substituent on the nitrogen atom and carbonyl bonded thereto can be used.
- a C-e alkanol such as formyl, acetyl, propionyl, pivaloyl and the like, and an acyl such as benzoyl can be used.
- a methylenedioxy group an ethylenedioxy group, a propylenedioxy group, a petylenedioxy group, or the like can be used. May be substituted on a different carbon.
- R 2 R 3 ', R 4 and R 5' substituent other than""replacement which may be optionally _ 6 alkoxy group” represented by And the same number of the same substituents as those used in the “optionally substituted alkyl group” as the substituent can be used.
- the same number of similar substituents as those used in the ⁇ optionally substituted alkyl group '' as the substituent may be used. Can be used.
- Optionally substituted acyl group '' represented by RR la , R 2 , R 2a , R 3 , R 3 ', R 3a , R 4 , R 4a , R 5 , R 5 ', R 5a and R 7
- substituent in the above the same number and the same as the substituents used in the “optionally substituted alkyl group” as the substituent Can be used.
- halogens such as fluorine, chlorine, bromine and iodine, trifluoromethanesulfonate, -toluenesulfonate, methanesulfonyl and the like can be used.
- Rings A and A A and rings B and B A may be substituted.
- X 1 , X 2 , XLA and the substituent in the ⁇ optionally substituted carbon atom '' represented by X 2A include those described above, R 2A , R 3 , R 3 ′, R 3A , R 4 , R One or two substituents similar to the substituents in the “optionally substituted hydrocarbon group” represented by 4A , R 5 , R 5 ′ and R 5A can be used.
- the “optionally substituted carbon atom” has no substituent, the carbon atom has one or two hydrogen atoms, and the “optionally substituted carbon atom” has one
- the carbon atom has 0 or 1 hydrogen atom in addition to the substituent.
- Examples of the substituent in the “optionally substituted nitrogen atom” represented by Y 21 and Y 2A include the above-mentioned R A , R 2 , R 3 ′, R 4 and R on the ring A or the ring B.
- a substituent in the “optionally substituted amino group” as a substituent in the definition of 5 ′ The same can be used.
- the nitrogen atom has 0 or 1 hydrogen atom.
- W and W 1 each represent a nitrogen atom or a group represented by the formula CR a (wherein the symbols represent the same groups as defined above). However, when the ring A represents a benzene ring which may be substituted, W represents a group represented by the formula CR a (wherein the symbols represent the same groups as defined above).
- Y 1 represents a group represented by the formula CR 2 R 3 (wherein each symbol represents the same group as defined above), and ⁇ represents a group represented by the formula CR 4 R 5 (where each symbol represents the same group as defined above.) ), A nitrogen atom, an oxygen atom, or a group represented by the formula S (0) m (wherein each symbol has the same meaning as defined above).
- Y 11 is a group represented by the formula CR3 ⁇ 4 3 ′ (wherein each symbol represents the same group as defined above.), Y 21 is 1) When W is a nitrogen atom, a formula CR 5 ′ (wherein Each symbol represents the same group as defined above.), A nitrogen atom, an oxygen atom or a group represented by the formula s (o) m (wherein the symbols have the same meanings as defined above).
- Y la is a group represented by the formula CR 2a R 3a (where each symbol represents the same group as defined above), and Y 2a is a group represented by the formula CR 4a R 5a (where each symbol is the same as defined above) ), A nitrogen atom, an oxygen atom or a group represented by the formula S (0, wherein each symbol has the same meaning as defined above.>).
- the compound of the present invention has the general formula
- each symbol is as defined above. Or a salt thereof.
- the A ring or A a ring particularly preferably benzene ring which may be substituted, optionally furan ring which may be substituted, an optionally substituted dihydrofuran ring, optionally substituted Shikuropen evening Gen ring, cyclopentene ring, optionally substituted cyclohexene ring, optionally substituted cyclohexene ring, optionally substituted dihydropyran ring, optionally substituted pyran ring, substituted Optionally substituted thiophene ring, optionally substituted pyrrolyl ring, optionally substituted pyridine ring, optionally substituted pyrroline ring, optionally substituted pyrrolidine ring, substituted An optionally used piperidine ring or the like can be used.
- Ring B or 'other Examples B a ring, particularly preferably, may pyrroline ring which may be substituted, an optionally substituted pyrrolidine ring, an optionally substituted piperidine be the ring, optionally substituted A morpholine ring, an optionally substituted thiomorpholine ring or an optionally substituted perhydroazepine ring.
- a cyano group, a nitro group, a halogen atom, a fluoromethyl group, a trifluoromethyl group and the like can be particularly preferably used.
- R 2 on the ring B the substituent group other than ', R 4 and R 5', particularly preferably hydrogen atom, a halogen atom, Shiano group, a nitro group, a hydroxyl group, an optionally substituted _ 6 Al
- a kill group eg, a methyl group, an ethyl group, a propyl group, a fluoromethyl group, a t: droxymethyl group, a hydroxyethyl group, a hydroxypropyl group, a methoxymethyl group, and the like
- a carbamoyl group, and the like can be used.
- the compound of the present invention is preferably a compound represented by the general formula (I) or the like, specifically, for example, 4-['-(hydroxymethyl) -11-piperidinyl] -111-naphthonitrile, 4- [ 3- (Hydroxymethyl) 1-1-piberidinyl]-1-naphthonitrile, 4- [3- (Hydroxymethyl) -1-3-methyl-1-piberidinyl] -11-naphthitol-2-tril, 4-1-1 (2-methyl-1-1) Pyrrolidinyl)-1-naphthonitrile, 4-((2-ethyl-1) -l-pyrrolidinyl) 1-l-naphthonitrile, 4- (2-vinyl-l-pyridinidinyl) -l-l-naphthonitrile, 4-l- (2-isopropyl-l 1) 1-Naphthonitrile, 4- (3-H
- B ring is further substituted by two may be cyclic ring, CR 4 or a nitrogen atom definitive in CR 2 or Y 21 in the Y 11 are a part of the B ring May be composed of, for example, a general formula
- Compounds according to the present invention can be produced by using a general organic synthesis method or by a known synthesis method. For example, it can be synthesized by the following method.
- a compound in which W or W 1 represents a nitrogen atom is, for example, a compound represented by the formula
- each symbol is as defined above.
- a salt thereof when the compound has a protecting group, the compound can be produced by removing the protecting group.
- the “leaving group” represented by M includes, for example, halogens such as fluorine, chlorine, bromine and iodine, 1) fluoromethanesulfonate, P-toluenesulfonate, and methanesulfonate. Nil or the like can be used.
- Compound (IV) or a salt thereof is generally used in an amount of 1 to 3 mol per 1 mol of compound (III).
- This reaction can be performed, if necessary, using potassium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium butbutoxide, potassium butbutoxide, triethylamine, diisopropylamine (DIEA), pyridine, 4- (dimethylamino). Pyridine (DMAP), 1,8-diazabicyclo [5,4,0] dex-1-7-ene (DBU), 1,5-diazabicyclo [4,3,0] non-1-5-ene (DBN) By adding a base, the reaction can also proceed smoothly. It is also preferable to use a transition metal catalyst (for example, J.O., 1997, 62, ppl264-1267) as the catalyst.
- a transition metal catalyst for example, J.O., 1997, 62, ppl264-1267
- the reaction is carried out in an inert solvent such as methanol, ethanol, propanol, isopropanol, n-butanol, tetrahydrofuran, geethylether, acetonitrile, acetone, ethyl acetate, 1,2-dimethyloxetane, 1,4-dioxane, toluene , Benzene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, DMF, dimethylsulfoxide, ND (DMS0) and the like, or a mixed solvent thereof.
- the reaction is performed in a temperature range from about 0 ° C to 180 ° C.
- the reaction time is not particularly limited, it is generally 0.1 hr to 100 hr, preferably 0.5 hr to 72 hr.
- the compound in which W or represents a nitrogen atom is also represented, for example, by the formula
- B b is a chain-like portion which becomes a Ba ring after reacting with the amino group of the above formula (V) to form a ring
- L 1 and L 2 are the same or different and represent a leaving group.
- Other symbols are as defined above.
- the “leaving groups” represented by L 1 and L 2 may be the same or different and include, for example, halogens such as fluorine, chlorine, bromine and iodine, and sulfo groups such as trifluoromethanesulfonyl, p-toluenesulfonyl, and methyl sulfonyl. Nyl groups can be used.
- Compound (VI) is generally used in 1 to 3 mol per 1 mol of compound (V) or a salt thereof. This reaction can be performed as necessary, using potassium carbonate, sodium carbonate, cesium carbonate, sodium bicarbonate, sodium 3 ⁇ 4K oxide, triethylamine, diisopropylamine (DIEA), pyridine, 4- (dimethylamino) pyridine (DMAP), 1,8-diazabicyclo. [5,4,0] Add bases such as 7-ene (DBU), 1,5-diazabicyclo [4,3,0] non-5-ene (DBN) and sodium iodide This allows the reaction to proceed smoothly.
- DBU 7-ene
- DBN 1,5-diazabicyclo
- DBN non-5-ene
- the reaction is carried out in an inert solvent such as methanol, ethanol, propanol, isopropanol, ⁇ -butanol, tetrahydrofuran, getyl ether, acetonitrile, acetone, ethyl acetate, 1,2-dimethoxyethane, 1,4
- the reaction can be carried out in dioxane, toluene, benzene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, DMF, dimethylsulfoxide (DMS0) or the like, or a mixed solvent thereof.
- the reaction is carried out in a temperature range from 0 to 180. While the reaction time is not particularly limited, it is generally 0.1 hr to 100 hr, preferably 0.5 hr to 24 hr.
- M 1 represents a leaving group or nitriloxide, and the other symbols have the same meanings as described above.
- R B and R e are the same or different and each represents a hydrogen atom, Shiano group, a nitro group, an optionally substituted Ashiru group, is also a good force Lupo cyclohexyl group or substituted optionally be esterified or amidated And a hydrocarbon group which may be used. And a salt thereof, and when the compound has a protecting group, the compound can be produced by removing the protecting group.
- the "leaving group" represented by MM 2 for example, fluorine, chlorine, bromine, halogen such as iodine, alkali metal, alkaline earth metal or their metal halide, halogenation zinc, tin halides, Torifuruo Methanesulfonate, p-toluenesulfonate, methanesulfonyl, dihydroxyporan, dialkoxyporan, and the like can be used.
- Compound (IX), (X) or a salt thereof is generally used in an amount of 1 to 3 mol per 1 mol of compound (VI II).
- This reaction can be performed as needed, using potassium carbonate, sodium carbonate, cesium carbonate , Sodium bicarbonate, sodium hydroxide, sodium t-butoxide, potassium t-butoxide, triethylamine, diisopropylamine (DIEA), pyridine, 4- (dimethylamino) pyridine (DMAP), 1, 8-diazahi: cyclo [
- bases such as [5,4,0] dex-1-7-ene (DBU) and 1,5-diazabicyclo [4,3,0] non-5-ene (DBN)
- DBU dex-1-7-ene
- DBN 1,5-diazabicyclo [4,3,0] non-5-ene
- the reaction is carried out in an inert solvent such as methanol, ethanol, propanol, isopropanol, n-butanol, tetrahydrofuran, geethylether, acetonitrile, acetone, ethyl acetate, 1,2-dimethoxyethane, 1,4-dioxane , Toluene, benzene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, DMF, dimethylsulfoxide (DMS0) and the like, or a mixed solvent thereof.
- the reaction is carried out at a temperature in the range of about 180 to 180 ° C.
- the reaction time is not particularly limited, but is usually 0.1 to 100 hours, preferably 0.5 to 72 hours.
- substituents on ring B in compound (I) or compound ( ⁇ ) can be converted to other substituents.
- the carbonyl group can be reduced to an alcohol, the alcohol can be dehydrated to an olefin, or the alcohol can be alkylated to an ether.
- Compounds (III), (IV), (V), (VI), (VI I), (VI 11), (IX), and (X) used as starting materials were synthesized by a known method or a method analogous thereto. For example, it can be produced by the method shown in the following Reference Example.
- the compounds (la), (IIa) and (lib) can also be synthesized by the above-mentioned method, a known method or a method analogous thereto.
- the group in the above formula may be protected by a protecting group used in general organic synthesis, and after the reaction, the protecting group can be removed by a known method if desired.
- compound (I) or the like When compound (I) or the like is obtained in a free form, it can be converted to a target salt by a method known per se or a method analogous thereto. It can be converted to a free form or another desired salt by a known method or a method analogous thereto.
- the compound (I) or the like may be a hydrate or a non-hydrate.
- the compound (I) or the like When the compound (I) or the like is obtained as a mixture of optically active substances, it can be separated into the desired (R) -form or (S) -form by a known optical resolution means.
- the compound (I) and the like may be labeled with an isotope (eg, 3 H, 14 C, etc.).
- the compounds in the present invention may form salts.
- the salt of the compound is not particularly limited as long as it does not inhibit the reaction.
- a salt with an inorganic base, an ammonium salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, and a salt with an amino acid Salts and the like are used.
- Preferred examples of the salt with an inorganic base include, for example, alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, and aluminum salt and ammonium salt.
- Preferred examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, 2,6-glutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine. , N, N, dibenzylethylenediamine and the like are used.
- Preferred examples of the salt with an inorganic acid include, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- Preferred examples of salts with organic acids include, for example, formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid Salts with acids, p-toluenesulfonic acid and the like are used.
- Preferred examples of the salt with a basic amino acid include, for example, salts with arginine, lysine, orditin, and the like.
- Preferred examples of the salt with an acidic amino acid include, for example, aspartic acid, dalminin A salt with an acid or the like is used.
- a prodrug of compound (I) or the like or a salt thereof is a compound that is converted into compound (I) by a reaction with an enzyme or gastric acid under physiological conditions in a living body, Oxidation, reduction, hydrolysis, etc., occur to convert to compound (I) A compound which is converted to a compound (I) by hydrolysis or the like by gastric acid or the like.
- Examples of the prodrug of compound (I) include compounds in which the amino group of compound (I) is acylated, alkylated, and phosphorylated (eg, the amino group of compound (I) is eicosaylated, alanylated, pentylamino).
- the prodrug of compound (I) can be obtained under the physiological conditions as described in Hirokawa Shoten, 1990, “Development of Drugs,” Volume 7, Molecular Design, pp. 163 to 198. (I) may be changed.
- the compound (I) of the present invention or a prodrug thereof has an androgen receptor modulator action, particularly an androgen receptor agonist action, and has an androgen receptor activity in mammals. It can be used for the prevention or treatment of diseases for which the administration of agonists is effective. Diseases for which androgen receptor agonist administration are effective include hypogonadism, osteoporosis, hormone-resistant cancer (especially LHRH agonist-resistant cancer), menopause (especially male menopause), anemia, arteriosclerosis, Alzheimer's disease Disease, erectile dysfunction, depression or wasting disease, and the like.
- the compound of the present invention is effective against breast cancer, prostatic cancer, endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, thyroid cancer, bone tumor, penis cancer, which has acquired hormone resistance among various cancers. 3 010228
- It can be used as a prophylactic or therapeutic agent, and is particularly useful as a prophylactic or therapeutic agent for prostate cancer.
- hormone-resistant cancer examples include LHRH derivative-resistant cancer, and preferably LHRH agonist-resistant cancer.
- the compound of the present invention has low toxicity, and can be used as a medicament as it is, or as a mixture with a pharmaceutically acceptable carrier known per se, in mammals (eg, humans, pests, mice, dogs, cats, rats, mice). , Rabbits, pigs, monkeys, etc.).
- a pharmaceutical composition the compound of the present invention and other active ingredients such as the following hormonal therapeutic agent, anticancer agent (for example, chemotherapeutic agent, immunotherapeutic agent, or cell growth factor and an agent that inhibits the action of its receptor, etc.) ) May be contained.
- the administration method is usually, for example, orally as tablets, capsules (including soft capsules and microcapsules), powders and granules, or as injections, It can be administered parenterally as suppositories, pellets and the like.
- Parenterally includes intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal, ophthalmic, intracerebral, rectal, vaginal and intraperitoneal, intratumoral, proximal tumor, etc. Or direct administration to the lesion.
- the dose of the compound of the present invention varies depending on the administration route, symptoms and the like.
- a patient body weight 40 to 80 kg
- breast cancer or prostate cancer as an anticancer agent
- l to 200 mg / kg body weight preferably 1 to 100 mg / kg body weight per day, more preferably 1 to 50 mg / kg body weight per day.
- This dose can be administered once a day or divided into two or three times a day.
- the compound of the present invention is mixed with a pharmaceutically acceptable carrier and administered orally or parenterally as a solid preparation such as tablets, capsules, granules and powders; or as a liquid preparation such as syrups and injections. be able to.
- various organic or inorganic carrier materials commonly used as pharmaceutical materials are used, and excipients, lubricants, binders, disintegrants in solid formulations; solvents in liquid formulations It is formulated as a solubilizer, suspending agent, isotonic agent, buffer, soothing agent, and the like. If necessary, pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can be used.
- the excipient include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light caffeic anhydride and the like.
- Suitable examples of the lubricant include, for example, magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include, for example, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyridone and the like.
- Preferred examples of the disintegrant include starch, carboxymethylcellulose, calcium propyloxymethylcellulose, croscarmellose sodium, carboxymethyl starch sodium and the like.
- Preferred examples of the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like.
- solubilizer examples include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; Hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose are used.
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate
- Hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose are used.
- Preferred examples of the tonicity agent include, for example, sodium chloride, glycerin, D-mannitol and the like.
- buffers such as phosphate, acetate, carbonate, and citrate.
- the soothing agent include benzyl alcohol and the like.
- Suitable examples of preservatives include, for example, paraoxybenzoic esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbin PT / JP2003 / 010228
- Preferred examples of the antioxidant include, for example, sulfite, ascorbic acid and the like.
- the pharmaceutical composition varies depending on the dosage form, administration method, carrier and the like, but is usually produced by including the compound of the present invention in an amount of 0.1 to 95% (w / w) with respect to the total amount of the preparation, according to a conventional method. be able to.
- non-drug therapies can prevent and treat cancer more effectively.
- non-drug therapy for example, surgery, radiation therapy, gene therapy, hyperthermia, cryotherapy, laser burn, and the like can be used, and two or more of these can be combined.
- the compound of the present invention may be used in combination with other hormonal therapeutic agents, anticancer agents (for example, chemotherapeutic agents, immunotherapeutic agents, or agents that inhibit the action of cell growth factors and their receptors), antiemetic agents, etc. Abbreviated) can be used in combination.
- anticancer agents for example, chemotherapeutic agents, immunotherapeutic agents, or agents that inhibit the action of cell growth factors and their receptors
- antiemetic agents etc. Abbreviated
- the compound of the present invention exhibits excellent anticancer activity even when used as a single agent, it can be further enhanced or used in combination with one or several of the above concomitant drugs (multiple drugs). Q0L can be improved.
- hormone therapeutic agent examples include: Phosfestrol, getylstilbest ore, chlorotrianiserin, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, cyproterone acetate, danazol, arylazole, guest Linone, meparttricin, raloxifene, olmeloxifene, repolmeloxifene, antiestrogens (eg, tamoxifen quenate, toremifene quenate, etc.), pill preparations, mepithiostan, testrolactone, aminoglutethimide, droloxifene, epipthios, sulfonic acid Ethynyl ester, aromatase inhibitor (eg, huadrozole hydrochloride, anastrozol, letrozole, exemestane, porozol, fluor Stann, etc.), anti-androgens
- chemotherapeutic agent for example, an alkylating agent, an antimetabolite, an anticancer antibiotic, a plant-derived anticancer agent and the like are used.
- alkylating agent examples include, for example, nitrogen mustard, nitrogen mustard hydrochloride-N-oxide, chlorambutyl, cyclophosphamide, difosfuamide, zotepa, lipocon, diprosulfan tosylate, busulfan , Dimustine hydrochloride, mitobronitol, melphalan, dacarbazine, ranimustine, sodium estramustine phosphate, triethylenemelamine, carmustine, lomustine, streptozocin, pipobroman, etogluside, carpoplatin, cis bratin, mipoplatin, nedaplatin, aledaplatin , Ambamustine, dibrospididium hydrochloride, fotemustine, prednisotine, bumitepa, lipomustine, temozofamide, treosulfan , Trofosfamide, dinostatin stimaramamer, lipo
- antimetabolites include, for example, mercaptopurine, 6-mercaptopurine riboside, thioinosine, methotrexate, enosinobin, shinorabin, citarabinofosfufoate, ansinobin hydrochloride, and 5-FU Drugs (eg, Fluorouracil, Tegafur, UFT, Doxyfluridine, Carmofur, Galocitabine, Emitefir, etc.), Aminobuterin, Leucoporin calcium, Tabloid, Butosin, Folinate calcium, Lepofluorinate calcium, Cladlipin, Emitefur Fludarabine, gemushibin, hydroxycarbamide, pentostin, pyrithrexim, idoxyperidine, mitguazone, thiazofurin, ambamustine and the like.
- 5-FU Drugs eg, Fluorouracil, Tegafur, UFT, Doxyfluridine, Carmofur, Galo
- anticancer ⁇ biomaterial
- biomaterial examples include actinomycin D, actinomycin C, mitomycin (:, chromomycin A3, bleomycin hydrochloride, pleomycin sulfate, bepromycin sulfate, daunorubicin hydrochloride, doxorubicin hydrochloride, axalubicin hydrochloride , Pirarubicin hydrochloride, epilubicin hydrochloride, neocarzinostatin, mi Suramycin, sarcomycin, carcinophilin, mitotane, sorbicin hydrochloride, mitoxantrone hydrochloride, idarubicin hydrochloride and the like are used.
- plant-derived anticancer agent for example, toposide, etoposide phosphate, pinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, paclitaxel, docetaxel, DJ-927, vinorelbine and the like are used.
- immunotherapeutic agent examples include, for example, picibanil, krestin, schizophyllan, lentinan, ubenimex, interferon, interleukin, macrophage colony stimulating factor, granulocyte co-stimulating factor, erythropoietin, Lymphotoxin, BCG vaccine, Corynebacterium parvum, revamisol, polysaccharide K, procodazole and the like are used.
- the “cell growth factor” in the “drug that inhibits the action of cell growth factor and its receptor” may be any substance that promotes cell growth, and usually has a molecular weight of 20,000 For the following peptides, factors that exert their effects at low concentrations by binding to receptors are used.
- EGF epidermal growth factor
- IGF insulin-like growth factor 1-1, IGF-2
- FGF fibroblast growth factor
- others Cell growth factors e.g., CSF (colony sti mulating factor) ⁇ EP ⁇ (erythropoietin), IL-2 (interleukin-2), NGF (nerve growth factor), PDGF (platelet-derived growth factor), TGF j3 (transforming growth factor ⁇ ), HGF (hepatocyte growth factor) , VEGF (vascular endothelial growth factor) and the like].
- CSF colony sti mulating factor
- EP ⁇ erythropoietin
- IL-2 interleukin-2
- NGF nerve growth factor
- PDGF platelet-derived growth factor
- TGF j3 transforming growth factor ⁇
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- the “cell growth factor receptor” may be any receptor as long as it has the ability to bind to the above-mentioned cell growth factor. Specifically, EGF receptor, halleglin receptor (HER2 ), Insulin receptor, IGF receptor, FGF receptor-11 or FGF receptor-12.
- the “drug that inhibits the action of cell growth factor” includes trastuzumab Tin (trademark); HER2 antibody), imatinib mesylate, ZD1839 or cetuximab.
- topo isomerase I inhibitor eg, irinotecan, nogitecan, execatecan (DX-8951f, DX-8951f, DE-310), rubitecan, T-0128, etc.
- topoisomerase II inhibitors eg, sobuzoxane
- the LH-RH derivatives include hormone-dependent diseases, particularly sex hormone-dependent cancers (eg, prostate cancer, uterine cancer, breast cancer, pituitary tumor, liver cancer, etc.), benign prostatic hyperplasia, endometriosis, uterine fibroids,
- hormone-dependent diseases particularly sex hormone-dependent cancers (eg, prostate cancer, uterine cancer, breast cancer, pituitary tumor, liver cancer, etc.), benign prostatic hyperplasia, endometriosis, uterine fibroids
- sex hormone-dependent diseases such as precocious puberty, dysmenorrhea, amenorrhea, premenstrual syndrome, and multilocular ovary syndrome, and contraception (or the rebound effect after drug withdrawal) are used, , Infertility) or an L ⁇ -RH derivative or a salt thereof is used.
- LH-RH derivatives or salts thereof which are effective for benign or malignant tumors which are sex hormone-independent but are L
- LH-RH derivative or its salt include, for example, Treatment with GnRH analog: Controversies and perspect ives [Zorileteno 1996 published by The Parthenon Publishing Group Ltd., Japanese Patent Publication No. 3-503165, Japanese Patent Laid-Open No. 3-101695, No. 7-97334 and No. 8-259460. The peptides described are used.
- LH-RH derivatives include LH-RH agonists and LH-RH antagonists.
- LH-RH antagonists include, for example,
- X is N and (4H 2 -furoyl) Gly or NAc
- A is negation eTyr, Tyr, Aph (Atz) , a residue selected from NMeAph (Atz)
- B is DLys (Nic), DCit, DLys (AzaglyNic), DLys (AzaglyFur )
- DhArg the (Et 2) residue selected from DAPH (Atz) and DhCi
- C is represented by Lys (Nisp), shown Arg or hArg the (Et 2), respectively]
- a physiologically active peptide or a salt thereof is used, and particularly preferred is abarelix, ganirelix, setlorelix, 5- (N-benzyl-N-methylaminoamino)-1- (2,6-difluorobenzoyl)- 6- [4- (3-Methoxyureido) phenyl] -3-phenylcheno [2,3-
- LH-RH agonist for example, LH-RH agonist
- Y is DLeu, DAla, DTrp, DSer ( tBu), D2Nal and DHis a residue selected from (ImBzl), Z is NH-C 2 or Gly- N are shown, respectively] bioactive Bae represented by Peptide or a salt thereof is used.
- bioactive Bae represented by Peptide or a salt thereof is used.
- Y in the DLeu, Z is NH-C 2 H 5 in which the peptide (i.e., 5 - Table 0X0- Pro- His- ⁇ ⁇ - Ser- Tyr- DLeu- Leu- Arg- Pro- at NH_C 2 H 5
- Preferred is peptide A; Ryuprolerin) or a salt thereof (eg, acetate).
- LH-RH agonist eg, goserelin acetate, buserelin, leuprorelin, etc.
- concomitant drug eg, goserelin acetate, buserelin, leuprorelin, etc.
- the timing of administration of the compound of the present invention and the concomitant drug% is not limited, and the compound of the present invention and the concomitant drug are simultaneously administered to a subject to be administered. It may be administered at a time interval.
- the dose of the concomitant drug may be in accordance with the dose clinically used, and can be appropriately selected depending on the administration subject, administration route, disease, combination, and the like.
- the administration form of the compound of the present invention and the concomitant drug is not particularly limited, as long as the compound of the present invention and the concomitant drug are combined at the time of administration.
- Such administration forms include, for example, (1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and a concomitant drug, and (2) separate administration of the compound of the present invention and the concomitant drug. Simultaneous administration of the two formulations obtained by formulation into the same route of administration, (3) separately preparing the compound of the present invention and the concomitant drug PT / JP2003 / 010228
- the concomitant drug of the present invention has low toxicity.
- the compound of the present invention or (and) the concomitant drug is mixed with a pharmacologically acceptable carrier according to a method known per se to obtain a pharmaceutical composition such as a tablet.
- a pharmaceutical composition such as a tablet.
- a pharmaceutical composition such as a tablet.
- a pharmaceutical composition such as a tablet.
- a pharmaceutical composition including sugar-coated tablets and film-coated tablets), powders, granules, capsules, (including soft capsules), liquids, injections, suppositories, sustained-release preparations, etc. , Topical, rectal, intravenous administration, etc.).
- Injectables are administered intravenously, intramuscularly, subcutaneously, in organs, intranasally, intradermally, instilled, in the brain, rectum, intravaginally and intraperitoneally, intratumorally, in the vicinity of tumors, or directly into tumors. It can be administered.
- the same carriers as those used in the aforementioned pharmaceutical composition of the present invention can be used.
- the compounding ratio of the compound of the present invention and the concomitant drug in the concomitant drug of the present invention can be appropriately selected depending on the administration subject, administration route, disease and the like.
- the content of the compound of the present invention in the concomitant drug of the present invention varies depending on the form of the preparation, but is usually about 0.01 to 100% by weight, preferably about 0. It is about 1 to 50% by weight, more preferably about 0.5 to 20% by weight.
- the content of the concomitant drug in the concomitant drug of the present invention varies depending on the form of the preparation, but is usually about 0.01 to 100% by weight, preferably about 0.1 to 50% by weight, based on the whole preparation. More preferably, it is about 0.5 to 20% by weight.
- the content of additives such as carriers in the concomitant drug of the present invention varies depending on the form of the preparation, but is usually about 1 to 99.9% by weight, preferably about 10 to 9% by weight, based on the whole preparation. It is about 0% by weight. Listen to PC 10228
- the same content may be used when the compound of the present invention and the concomitant drug are separately formulated.
- preparations can be produced by a method known per se that is generally used in the preparation process.
- the compound of the present invention or the concomitant drug may be a dispersant (eg, Tween 80 (manufactured by Atlas Powder Co., USA), HC060 (manufactured by Nikko Chemicals), polyethylene glycol, carboxymethylcellulose, sodium alginate, hydroxyp Pill methyl cellulose, dextrin, etc.), stabilizer (eg, ascorbic acid, sodium bisulfite, etc.), surfactant (eg, polysorbate 80, macrogol, etc.), solvent (eg, glycerin, ethanol) ), Buffering agents (eg, phosphoric acid and its alkali metal salts, citric acid and its alkali metal salts, etc.), tonicity agents (eg, sodium chloride, potassium chloride, mannitol, sorbitol, glucose, etc.), pH regulation Agent (eg, hydrochloric acid, sodium hydroxide, etc.), preservative (eg, paraoxybenzoate) Ethyl
- the compound of the present invention or the concomitant drug is used in a manner known per se, for example, excipients (eg, lactose, sucrose, starch, etc.), disintegrants (eg, starch, calcium carbonate, etc.) , A binder (eg, starch, gum arabic, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, etc.) or a lubricant (eg, talc, magnesium stearate, polyethylene glycol 600, etc.) It can be made into an oral preparation by compression molding and then, if necessary, coating it with a method known per se for the purpose of taste masking, enteric coating or sustainability.
- excipients eg, lactose, sucrose, starch, etc.
- disintegrants eg, starch, calcium carbonate, etc.
- a binder eg, starch, gum arabic, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropyl
- the coating agent examples include hydroxypropyl methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxybutyl pillcellulose, polyoxyethylene glycol, Tween 80, and Pluronic.
- F 68 cellulose acetate phthalate, hydroxypropyl methylcellulose monophosphate, hydroxymethylcellulose acetate succinate, Eudragit (Rohm, Germany, methacrylic acid / acrylic acid copolymer) and dyes (eg And the like.
- the preparation for oral administration may be either a quick release preparation or a sustained release preparation.
- the compound of the present invention or the concomitant drug can be converted into an oily or aqueous solid, semi-solid or liquid suppository according to a method known per se.
- the oily base used in the composition include glycerides of higher fatty acids (eg, cocoa butter, witepsols (manufactured by Dynamite Nobel, Germany), etc.), intermediate fatty acids [eg, miglyols (manufactured by Dynamite Nobel) , Germany) or vegetable oils (eg, sesame oil, soybean oil, cottonseed oil, etc.).
- aqueous base examples include polyethylene glycols and propylene glycol
- examples of the aqueous gel base include natural gums, cellulose derivatives, bier polymers, and acrylic acid polymers.
- sustained-release preparation a sustained-release capsule with a mic mouth is used.
- a method known per se can be used to prepare sustained-release microcapsules. For example, it is preferable to administer a sustained-release preparation shown in the following [2] by molding.
- the compound of the present invention is preferably formed into a preparation for oral administration such as a solid preparation (eg, powder, granules, tablets, capsules) or a preparation for rectal administration such as a suppository.
- a preparation for oral administration such as a solid preparation (eg, powder, granules, tablets, capsules) or a preparation for rectal administration such as a suppository.
- preparations for oral administration are preferred.
- the concomitant drug can be in the above-mentioned dosage form depending on the kind of the drug.
- An injection prepared by dissolving the compound of the present invention or the concomitant drug in water is preferred.
- the injection may contain a benzoate or a benzoate and a salicylate.
- the injection can be obtained by dissolving the compound of the present invention or the concomitant drug and, if desired, both a benzoate or a salt thereof with water.
- the salts of benzoic acid and salicylic acid include alkaline metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, ammonium salts, meglumine salts, and organic acid salts such as trometamol. Used.
- the concentration of the compound of the present invention or the concomitant drug in the injection is about 0.5 to 5 OwZv%, preferably about 3 to 20 wZv%.
- the concentration of benzoate or Z and salicylate is 0.5 to 50 w / v%, preferably 3 to 2 O wZv%.
- This drug also contains additives commonly used in injections, such as stabilizers (ascorbic acid, sodium pyrosulfite, etc.), surfactants (polysorbate 80, macrogol, etc.), and solvents (glycerin, ethanol).
- stabilizers ascorbic acid, sodium pyrosulfite, etc.
- surfactants polysorbate 80, macrogol, etc.
- solvents glycolin, ethanol
- buffering agents phosphoric acid and its alkali metal salts, citric acid and its alkali metal salts, etc.
- tonicity agents sodium chloride, potassium chloride, etc.
- dispersants hydroxypropyl methylcell ore, dextrin
- PH adjusters hydroochloric acid, sodium hydroxide, etc.
- preservatives ethyl ethyl parabenzoate, benzoic acid, etc.
- solubilizers Concentrated glycerin, medalmine, etc.
- solubilizers propylene glycol, sucrose, etc.
- soothing Agents glucose, benzyl alcohol, etc.
- these additives are generally blended in a ratio usually used for an injection.
- the injection is preferably adjusted to 2 to 12, preferably 2.5 to 8.0 by adding a pH regulator.
- Injectables are obtained by dissolving the compound of the present invention or the concomitant drug and, if desired, both benzoate or Z and salicylate, and if necessary, the above-mentioned additives in water. These dissolutions may be performed in any order, and can be appropriately performed in the same manner as in the conventional method for producing an injection.
- the aqueous solution for injection is preferably heated, and can be used as an injection by performing, for example, sterilization by filtration, high-pressure heat sterilization, or the like in the same manner as an ordinary injection.
- the aqueous solution for injection is preferably subjected to high-pressure heat sterilization at 100: to 121 ° C for 5 minutes to 30 minutes, for example.
- a formulation having antimicrobial properties of the solution may be used so that it can be used as a multiple-dose formulation.
- Sustained-release preparation or immediate-release preparation and its preparation A sustained-release preparation obtained by coating a nucleus containing the compound of the present invention or the concomitant drug with a coating agent such as a water-insoluble substance or a swellable polymer as desired is preferable. For example, a once-per-day sustained release preparation for oral administration is preferred.
- water-insoluble substance used for the coating agent examples include cellulose ethers such as ethyl cellulose and butyl cellulose, cellulose acetates such as cellulose acetate and cellulose acetate, polyvinyl acetate, and polypinyl butyrate.
- the swellable polymer a polymer having an acidic dissociating group and exhibiting a pH-dependent swelling is preferable.
- the swelling polymer has a small swelling in an acidic region such as the stomach and a large swelling in a neutral region such as the small intestine and the large intestine.
- Polymers having acidic dissociative groups are preferred.
- Polymers having such an acidic dissociating group and exhibiting pH-dependent swelling include, for example, polycarbophils such as 934P, 940, 941, 974P, 980, 1342, and the like. And crosslinked polyacrylic acid polysaccharides such as calcium polycarbophil (both from BF Goodrich Co., Ltd.), Hibis Pico 103, 104, 105 and 304 (all from Wako Pure Chemical Industries, Ltd.) Coalescing is used.
- the coating agent used in the sustained-release preparation may further contain a hydrophilic substance.
- the hydrophilic substance include polysaccharides which may have a sulfate group such as pullulan, dextrin, alkali metal alginate, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose sodium and the like. Polysaccharides having a hydroxyalkyl group or a carboxyalkyl group, methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene dalicol and the like are used.
- the content of the water-insoluble substance in the coating agent of the sustained-release preparation is about 30 to about 90% (w / w), preferably about 35 to about 80% (w / w), more preferably about 4 0 to 75% (w / w), swellable polymer content of about 3 to about 30% (w / w), preferably about 3 to about 15% (w / w) .
- the coating agent may further comprise a hydrophilic substance, in which case the content of the hydrophilic substance in the coating agent is not more than about 50% (w / w), preferably about 5 to about 40% (w / w). / w), more preferably from about 5 to about 35% (w / w).
- the above-mentioned% (w / w) indicates the weight% based on the coating agent composition obtained by removing the solvent (eg, water, methanol, lower alcohol such as ethanol, etc.) from the coating agent liquid.
- a core containing a drug is prepared as exemplified below, and the obtained core is then dissolved by heating or dissolving or dispersing a water-insoluble substance or a swellable polymer in a solvent. It is manufactured by coating with
- the form of the nucleus containing the drug to be coated with the coating agent (hereinafter sometimes simply referred to as the nucleus) is not particularly limited, but is preferably formed in the form of granules or fine particles.
- the average particle size is preferably about 150 to 2,000 urn, more preferably about 500 to about 1,400 m.
- the nucleus can be prepared by a usual production method.
- a suitable excipient, a binder, a disintegrant, a lubricant, a stabilizer, and the like are mixed with a drug, and the mixture is prepared by wet extrusion granulation, fluidized bed granulation, or the like.
- the drug content of the core is from about 0.5 to about 95% (w / w), preferably from about 5.0 to about 80% (w / w), more preferably from about 30 to about 70% (w / w). w / w).
- excipients contained in the core include sugars such as sucrose, lactose, mannitol, and glucose, starch, crystalline cellulose, calcium phosphate, corn starch, and the like. You. Among them, crystalline cellulose and corn starch are preferred.
- binder for example, polypinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, polyvinylpyrrolidone, pull nick F68, gum arabic, gelatin, starch and the like are used.
- Disintegrators include, for example, carboxymethyl cellulose calcium (ECG505), croscarmellose sodium (Ac-Di-Sol) ', cross-linked polyvinylpyrrolidone (crospovidone), low-substituted hydroxypropylcells HPC) is used.
- hydroxypropylcellulose, polyvinylpyrrolidone and low-substituted hydroxypropylcellulose are preferred.
- talc, magnesium stearate and inorganic salts thereof are used as a lubricant and an anti-agglomeration agent, and polyethylene glycol and the like are used as a lubricant.
- Acids such as tartaric acid, citric acid, succinic acid, fumaric acid and maleic acid are used as stabilizers.
- the nucleus may be formed by spraying a binder dissolved in a suitable solvent such as water or lower alcohol (eg, methanol, ethanol, etc.) on inert carrier particles serving as the center of the nucleus, in addition to the above-mentioned production method. It can also be prepared by the tumbling granulation method, pan coating method, fluidized bed coating method, or melt granulation method in which a small amount of a drug or a mixture of this and an excipient, a lubricant, etc. is added. .
- the inert carrier particles for example, those made of sucrose, lactose, starch, crystalline cellulose, and waxes can be used, and the average particle diameter is about 100 m to about 1,500 Atm. Is preferred.
- the surface of the nucleus may be coated with a protective agent.
- a protective agent for example, the above-mentioned hydrophilic substance, water-insoluble substance and the like are used.
- a polysaccharide having a polyethyleneglycol-hydroxyalkyl group or a hydroxypropylalkyl group, preferably hydroxypropylmethylcellulose or hydroxypropylcellulose is used.
- the protective agent may contain, as a stabilizer, an acid such as tartaric acid, citric acid, succinic acid, fumaric acid, and maleic acid, and a lubricant such as talc.
- its coating amount is about 1 to about 15% (w / w), preferably about 1 to about 10% (w / w), more preferably about 2 to about 8% (w / w).
- the protective agent can be coated by a usual coating method. Specifically, the protective agent is spray-coated on the nucleus by, for example, a fluidized bed coating method or a bank coating method. PC orchid painting 10228
- the nucleus obtained in I is covered with a coating agent solution in which the water-insoluble substance, the pH-dependent swellable polymer, and the hydrophilic substance are dissolved by heating or dissolved or dispersed in a solvent. An active preparation is produced.
- a spray coating method or the like is used as a method for coating the nucleus with the coating agent solution.
- composition ratio of the water-insoluble substance, the swellable polymer or the hydrophilic substance in the coating agent solution is appropriately selected such that the content of each component in the coating becomes the above-mentioned content.
- the coating amount of the coating agent is about 1 to about 90% (w / w), preferably about 5 to about 50% (/ w), more preferably about the core (not including the protective agent). Is about 5 to 35% (w / w).
- water or an organic solvent can be used alone or in a mixture of both.
- the mixing ratio of water and the organic solvent (water Z organic solvent: weight ratio) when using the mixed solution can be changed in the range of 1 to 100%, and preferably 1 to about 30%.
- the organic solvent is not particularly limited as long as it dissolves a water-insoluble substance. Examples thereof include lower alcohols such as methyl alcohol, ethyl alcohol, isopropyl alcohol, and n-butyl alcohol; lower alcohols such as acetone, and lower alcohols such as acetone. Cetonitrile, chloroform, methylene chloride and the like are used. Of these, ethyl alcohol and isopropyl alcohol, which are preferred for lower alcohols, are particularly preferred.
- Water and a mixture of water and an organic solvent are preferably used as a solvent for the coating agent.
- an acid such as tartaric acid, citric acid, succinic acid, fumaric acid, or maleic acid may be added to the coating agent solution for stabilizing the coating agent solution.
- the operation for coating by spray coating can be performed by a usual coating method.
- the coating agent is spray-coated on the core by, for example, a fluidized bed coating method or a pan coating method.
- a fluidized bed coating method or a pan coating method can be implemented at At this time, if necessary, use talc, titanium oxide, magnesium stearate, calcium stearate, light citric anhydride, etc. as lubricants, glycerin fatty acid ester, hydrogenated castor oil, triethyl quenate, cetyl alcohol, stearyl alcohol 2003/010228
- an antistatic agent such as talc may be mixed as necessary.
- the immediate-release preparation may be liquid (solution, suspension, emulsion, etc.) or solid (particles, pills, tablets, etc.).
- Parenteral preparations such as oral preparations and injections are used, but oral preparations are preferred.
- Immediate release preparations may generally contain, in addition to the active ingredient drug, carriers, additives and excipients (hereinafter sometimes abbreviated as excipients) commonly used in the pharmaceutical field.
- excipients commonly used in the pharmaceutical field.
- the formulation excipient used is not particularly limited as long as it is a commonly used excipient.
- excipients for oral solid preparations lactose, starch, corn starch, crystalline cellulose (Avicel PH101, etc., manufactured by Asahi Kasei Corporation), powdered sugar, dara niyu sugar, mannitol, light caffeic anhydride, Magnesium carbonate, calcium carbonate, L-cysteine and the like are used, and corn starch and mannitol are preferably used.
- excipients can be used alone or in combination of two or more.
- the content of the excipient is, for example, about 4.5 to about 99.4 w / w%, preferably about 20 to about 98.5 w / w%, more preferably about the whole amount of the immediate-release preparation. Is from about 30 to about 97 w / w%.
- the content of the drug in the immediate-release preparation can be appropriately selected from the range of about 0.5 to about 95%, preferably about 1 to about 60%, based on the total amount of the immediate-release preparation.
- the immediate release preparation When the immediate release preparation is an oral solid preparation, it usually contains a disintegrant in addition to the above components.
- disintegrants include carboxymethylcellulose calcium (Gotoku Yakuhin, ECG-505), croscarmellose sodium (for example, Asahi Kasei Corporation, Accadizol), and crospovidone (for example, BASF Corporation, Kolydone CL), low-substitution hydroxypropylcellulose (Shin-Etsu Chemical Co., Ltd.), carboxymethyl starch (Matsuya Chemical Co., Ltd.), carboxymethyls yuichi chinatorium (Kimura Sangyo, Explotab), partial ⁇ Chemically modified starch (PCS, manufactured by Asahi Kasei Corporation) is used, for example, by contacting with water to absorb, swell, or form a channel between the active ingredient constituting the core and the excipient, etc.
- PCS partial ⁇ Chemically modified starch
- disintegrants can be used alone or in combination of two or more.
- the blending amount of the disintegrant is appropriately selected depending on the type and blending amount of the drug to be used, the design of the release preparation, and the like. For example, about 0.05 to about 30 w / w%, preferably about 0.5 to about 15 w / ' JP2003 / 010228
- the solid preparation may optionally further contain a conventional additive.
- additives include binders (eg, sucrose, gelatin, gum arabic, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, pullulan, dextrin, etc.), Lubricants (for example, polyethylene glycol, magnesium stearate, talc, light caffeic anhydride (for example, aerosil (Nippon Aerosil)), surfactants (for example, anionic surfactants such as sodium alkyl sulfate, polio) Non-ionic surfactants such as xyethylene fatty acid esters, polyoxyethylene sorbin fatty acid esters, and polyoxyethylene castor oil derivatives, etc.), and coloring agents (for example, tar dyes, caramel, bengala, acid) Tanf
- binders eg, sucrose, gelatin, gum arabic, methylcellulose, hydroxypropylcellulose, hydroxyprop
- hydroxypropylcellulose polyethylene glycol and polyvinylpyrrolidone are preferably used.
- An immediate release preparation can be prepared by mixing the above-mentioned components, further kneading and shaping the mixture, if necessary, based on a usual preparation production technique.
- the mixing is performed by a generally used method, for example, mixing, kneading, and the like.
- a rapid-release preparation is formed into particles, the same method as that for preparing the core of the sustained-release preparation can be used. It can be prepared by mixing using a fluidized bed granulator FD-5S (manufactured by PALEC), etc., and then granulating by wet extrusion granulation, fluidized bed granulation, etc. .
- the immediate-release preparations and sustained-release preparations thus obtained can be formulated as they are, or separately and appropriately, together with pharmaceutical excipients, etc., in a conventional manner, and then administered simultaneously or in combination at arbitrary intervals.
- the preparation may be formulated into a single oral administration preparation (eg, granules, fine granules, tablets, capsules, etc.) together with the preparation excipients or the like as they are or as appropriate. Make both preparations into granules or fine granules and fill them in the same capsule, etc. It may be filled into a preparation for oral administration.
- the sublingual tablet, the puccal preparation, and the quick disintegrating agent in the oral cavity may be a solid preparation such as a tablet or an oral mucosa patch (film).
- a preparation containing the compound of the present invention or the concomitant drug and an excipient is preferable.
- auxiliary agents such as a lubricant, a tonicity agent, a hydrophilic carrier, a water-dispersible polymer and a stabilizer may be contained.
- a [3-cyclodextrin or a [3-cyclodextrin derivative eg, hydroxypropyl-1] 3-cyclodextrin, etc.
- lactose, saccharose, D-mannitol, starch, crystal cell mouth, light caffeic anhydride and the like are used.
- lubricant magnesium stearate, calcium stearate, talc, colloidal silica and the like are used, and magnesium stearate / colloidal silica is particularly preferable.
- tonicity agents sodium chloride, glucose, flux I, mannyl !, sorby! , Saccharose, glycerin, urea and the like are used, and mannitol is particularly preferable.
- hydrophilic carrier swellable hydrophilic carriers such as crystalline cellulose, ethyl cellulose, crosslinkable polyvinylpyrrolidone, light anhydrous silicic acid, silicic acid, dicalcium phosphate, and calcium carbonate are used.
- crystalline cellulose eg, microcrystalline And cellulose are preferred.
- Water-dispersible polymers include gums (eg, tragacanth, acacia, guar gum), alginates (eg, sodium alginate), cellulose derivatives (eg, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxypro Pilulcellulose, hydroxypropylmethylcellulose), gelatin, water-soluble starch, polyacrylic acid (eg, Riki-boma), polymethacrylic acid, polypinyl alcohol, polyethylene glycol, polyvinylpyrrolidone, polyphenol pofil, vas Corbic acid palmitate and the like are used, hydroxypropyl methylcellulose, polyacrylic acid, alginate, gelatin, carboxymethylcellulose, polyvinylpyrrolidone, polyethylene glycol Etc. are preferred. Particularly, hydroxypropyl methylcellulose is preferable.
- cysteine, thiosorbitol, PT / JP2003 / 010228 As stabilizers, cysteine, thiosorbitol,
- Tartaric acid, cunic acid, sodium carbonate, ascorbic acid, glycine, sodium sulfite and the like are used, and in particular, diascorbic acid citrate is preferred.
- the sublingual tablet, buccal or intraoral quick disintegrating agent can be produced by mixing the compound of the present invention or the concomitant drug with an excipient by a method known per se. Further, if necessary, the above-mentioned auxiliary agents such as a lubricant, an isotonic agent, a hydrophilic carrier, a water-dispersible polymer, a stabilizer, a coloring agent, a sweetener, and a preservative may be mixed.
- the sublingual tablet, buccal tablet, or rapidly disintegrating tablet in the oral cavity can be obtained by mixing the above components at the same time or with a time interval and then press-molding. In order to obtain an appropriate hardness, the tablet may be produced by humidifying and wetting with a solvent such as water or alcohol as needed before and after the tableting process, followed by molding and drying.
- the compound of the present invention or the concomitant drug and the above-mentioned water-dispersible polymer preferably hydroxypropylcell mouth, hydroxypropylmethylcell mouth
- excipient preferably hydroxypropylcell mouth, hydroxypropylmethylcell mouth
- a solvent such as water
- additives such as a plasticizer, a stabilizer, an antioxidant, a preservative, a coloring agent, a buffer, and a sweetener may be added.
- Glycols such as polyethylene glycol and propylene glycol may be included to impart appropriate properties to the film, and bioadhesive polymers (eg, PolyRypofil, Rypopol, etc.) may be used to enhance the adhesion of the film to the mucosal lining of the oral cavity. ) May be contained.
- bioadhesive polymers eg, PolyRypofil, Rypopol, etc.
- a uniform thickness preferably about 100 to 100 microns
- a coating tool such as a doctor blade
- a preferred rapid intraoral disintegrant is a solid rapid diffusion administration comprising a network of the compound of the present invention or the concomitant drug and a water-soluble or water-diffusible carrier inactive with the compound of the present invention or the concomitant drug.
- Agent is used.
- the network can be obtained by sublimating the solvent from the solid composition composed of a solution of the compound of the present invention or the concomitant drug in a suitable solvent.
- the composition of the intraoral quick disintegrating agent contains a matrix forming agent and a secondary component in addition to the compound of the present invention or the concomitant drug.
- the matrix-forming agent include gelatins, dextrins, and animal or vegetable proteins such as soybean, wheat, and psylium seed proteins; gum materials such as gum arabic, guar gum, agar, and xanthan; Polysaccharides; alginic acids; carboxymethylcellulose; carrageenans; dextrans; pectins; synthetic polymers such as polybierpyrrolidone; and substances derived from gelatin-arabia gum complex and the like.
- sugars such as mannitol, dextrose, lactose, galactose and trehalose; cyclic sugars such as cyclodextrin; inorganic salts such as sodium phosphate, sodium chloride and aluminum silicate; glycine, L-aranan, L-aspartic acid, L-glutamic acid And L-hydroxyproline, L-isoleucine, L-mouth isine, and amino acids having 2 to 12 carbon atoms, such as L-phenylalanine.
- One or more of the matrix formers can be introduced into a solution or suspension before solidification.
- a matrix-forming agent may be present in addition to the surfactant, or may be present without the surfactant.
- Matrix formers in addition to forming their matrix, can help maintain the compound of the present invention or concomitant drug in a dispersed state in the solution or suspension.
- Suitable colorants include red, black and yellow iron oxides and FD & C dyes such as FD & C Blue 2 and FD & C Red 40 from Ellis 'and' Everard.
- Suitable flavors include mint, raspberry, licorice, orange, lemon, grapefruit, caramel, vanilla, teeri, and grape flavors and combinations thereof.
- Suitable pH adjusters include citric acid, tartaric acid, phosphoric acid, hydrochloric acid and maleic acid.
- Suitable sweeteners include aspartame, acesulfame K and thaumatin.
- Suitable taste masking agents include sodium bicarbonate, ion exchange resins, cyclodextrin inclusion compounds, adsorbate materials, and microencapsulated apomorphine.
- the formulations usually contain from about 0.1 to about 50% by weight, preferably from about 0.1 to about 30% by weight, of the compound of the present invention or the concomitant drug, preferably for about 1 minute to about 60 minutes. Is a formulation capable of dissolving 90% or more of the compound of the present invention or the concomitant drug (in water) between about 1 minute and about 15 minutes, more preferably between about 2 minutes and about 5 minutes.
- the content of the excipient in the whole preparation is about 10 to about 99% by weight, preferably about 30 to about 90% by weight.
- the content of the J3-cyclodextrin or the 3-cyclodextrin derivative in the whole preparation is 0 to about 30% by weight.
- the content of the lubricant in the whole preparation is about 0.01 to about 10% by weight, preferably about 1 to about 5% by weight.
- the content of the tonicity agent in the whole preparation is about 0.1 to about 90% by weight, preferably about 10 to about 70% by weight.
- the content of the hydrophilic carrier in the whole preparation is about 0.1 to about 50% by weight, preferably about 10 to about 30% by weight.
- the content of the water-dispersible polymer with respect to the whole preparation is about 0.1 to about 30% by weight, preferably about 10 to about 25% by weight.
- the content of the stabilizer relative to the whole preparation is about 0.1 to about 10% by weight, preferably about 1 to about 5% by weight.
- the preparation may further contain additives such as a coloring agent, a sweetening agent and a preservative, if necessary.
- the dosage of the concomitant drug of the present invention varies depending on the type, age, body weight, symptom, dosage form, administration method, administration period, and the like of the compound of the present invention.
- prostate cancer patients adults, about 60 kg in weight
- the concomitant drug respectively, about 0.01 to about 1000 mgZkg / day, preferably about 0.01 to about 100 mgZkg / day, more preferably About 0.1 to about 10 Omg / kg, especially about 0.1 to about 5 Omg / kg, especially about 1.5 to about 30 mg / kg, once to several times a day It is administered intravenously.
- the dose varies under various conditions, so that a smaller dose may be sufficient in some cases, or it may be necessary to administer a dose outside the range.
- the concomitant drug can be used in any amount as long as side effects are not a problem.
- the daily dose of the concomitant drug varies depending on the severity of symptoms, age, gender, body weight, sensitivity difference, administration timing, interval, characteristics of pharmaceutical preparation, preparation, type, type of active ingredient, etc.
- the amount of the drug is usually, for example, oral administration T / JP2003 / 010228
- the concomitant drug may be administered at the same time.However, after administering the concomitant drug first, the compound of the present invention may be administered, or the compound of the present invention may be administered first. Thereafter, the concomitant drug may be administered.
- the time difference varies depending on the active ingredient, dosage form and administration method to be administered.For example, when the concomitant drug is administered first, within 1 minute to 3 days after administration of the concomitant drug, preferably A method of administering the compound of the present invention within 10 minutes to 1 day, more preferably within 15 minutes and 1 hour is used.
- the concomitant drug is administered within 1 minute to 1 day, preferably within 10 minutes to 6 hours, more preferably within 15 minutes to 1 hour after administering the compound of the present invention. A method is used.
- the pharmaceutical composition of the present invention or the concomitant drug of the present invention may be used, for example, in (1) surgery, (2) pressor chemotherapy using angiotensin II or the like, (3) gene therapy, (4) hyperthermia, It can be combined with non-drug therapy such as 5) cryotherapy, (6) laser cautery, and (7) radiation therapy.
- the pharmaceutical composition of the present invention or the concomitant drug of the present invention before or after surgery or the like, or before or after treatment combining these two or three kinds, the prevention of resistance development, disease-free stage (Disease-Free Survival), suppress cancer metastasis or recurrence, and prolong life.
- treatment with the pharmaceutical composition of the present invention or the concomitant drug of the present invention, and supportive therapy [(i) antibiotics against complications of various infectious diseases (for example, macrophages such as / 3-lactams such as pansporin and clarithromycin) (Ii) high-calorie infusion for improving nutritional disorders, administration of amino acid preparations and multivitamin preparations, (iii) administration of morphine for pain relief, (iv) nausea, vomiting, anorexia Improves side effects such as diarrhea, leukopenia, thrombocytopenia, decreased hemoglobin concentration, hair loss, liver damage, kidney damage, DIC, fever, etc. And (v) administration of a drug for suppressing multidrug resistance of cancer, etc.).
- antibiotics against complications of various infectious diseases for example, macrophages such as / 3-lactams such as pansporin and clarithromycin
- drugs for such purposes include 5-dancer such as ondansetron, tropisetron hydrochloride, azasetron, ramosetron, khaisetron, dolasetron mesilet, and palonosetron.
- 5-dancer such as ondansetron, tropisetron hydrochloride, azasetron, ramosetron, khaisetron, dolasetron mesilet, and palonosetron.
- NK1 receptor antagonists such as sendi de, CP-99994, CP-100263, CP-122721-1, CP-96345, FK224, RPR100893, NKP608, aprepitant (EMEND (TM)); domperidone Gastrointestinal motility enhancers such as 5-HT4 antagonists such as, mosapride and metoclobramide; Gastrointestinal motility regulants such as trimeptin; Phenothiazines such as prochlorperazine maleate, promethazine and cetylperazine; Tranquilizers such as haloperidol, chlorpromazine phenolphthalate, diazepam, droperidol; Dexa Steroids such as data Zon, prednisolone, betamethasone, triamcinolone and the like; other, dimethyl hydrin acid, diphenhydramine, hyoscine, hydrobromic hyoscine, be used as
- the pharmaceutical composition of the present invention or the concomitant drug of the present invention is orally administered (including sustained release), intravenous administration (including bolus, infusion, clathrate), subcutaneous It is preferably administered by intramuscular injection (including bolus, infusion, sustained release), transdermal, intratumoral and proximal administration.
- the time when the pharmaceutical composition of the present invention or the concomitant drug of the present invention is administered before surgery or the like may be, for example, administration once about 30 minutes to 24 hours before surgery or the like, or It can also be administered in 1 to 3 cycles about 3 to 6 months before.
- the pharmaceutical composition of the present invention or the concomitant drug of the present invention before surgery or the like for example, the cancer tissue can be reduced, and thus the surgery or the like becomes slow.
- the time when the pharmaceutical composition of the present invention or the concomitant drug of the present invention is administered after surgery or the like may be repeated about 30 minutes to 24 hours after the surgery or the like, for example, every several weeks to three months. it can.
- the effects of surgery or the like can be enhanced.
- the present inventors surprisingly found that the androgen receptor agonist suppresses the growth of hormone-resistant cancer, and that the androgen receptor agonist having a nonsteroidal skeleton, such as the compound of the present invention, is effective in suppressing hormone-resistant cancer. It was found to be useful for prevention and treatment.
- Another object of the present invention is to provide a method for preventing and treating hormone-resistant cancer by administering an androgen receptor agonist, and an agent for preventing and treating hormon-resistant cancer comprising an androgen receptor agonist.
- steroidal androgen receptor agonist and nonsteroidal androgen receptor agonist can be used.
- steroidal androgen receptor agonists endogenous androgens such as dehydroepiandrosterone (dehydroepiandrosterone), testosterone (testosterone; dihydrotestosterone (DHT), androstendione (androstendione), and mestanolone (Mes tanolone) 1 one), oxymesterone (Oxymes terone), methandrostenolone (Met handros t eno 1 one), Fluoxymes terone (Fluoxymes terone), Chlorotestosterone acetate (Chlorotestosterone acetate), Methenolone acetate (Methenolone acetate), Oxymetholone, Stanozolol, Furazapol, Oxandrolone, 19-Nortestosterone, Norethandrolone, Ethyl
- LGD-2226 in addition to the compound (I) of the present invention, LGD-2226 and the like can be used.
- the above-mentioned compounds can be used alone or in combination of two or more compounds, and a non-steroidal androgen receptor agonist is particularly preferable.
- Cancers include prostate cancer and the like.
- hormone-resistant cancer examples include LHRH derivative-resistant cancer.
- LHRH derivative-resistant prostate cancer Preferably LHRH derivative-resistant prostate cancer, more preferably LHRH agonist resistance And LHRH agonist resistant prostate cancer.
- the same compounds as defined above can be used.
- an effective amount of an LHRH derivative or a salt thereof is administered to a mammal having prostate cancer cells, and after the prostate cancer cells become hormone-resistant, the androgen receptor agonist (particularly nonsteroidal Androgen receptor agonist) or a salt thereof in an effective amount,
- Androgen receptor agonist especially nonsteroidal androgen receptor agonist
- LHRH derivative especially nonsteroidal androgen receptor agonist
- lyase inhibitor especially aromatase
- Increased hormone resistance of prostate cancer cells by administering an effective amount of an LHRH derivative, a lyase inhibitor, an aroma inhibitor or an antiandrogen or a salt thereof for a certain period of time (for example, 3 months to 5 years) There is. Thereafter, by administering an effective amount of an androgen receptor agonist (particularly a nonsteroidal androgen receptor agonist) or a salt thereof, the growth of prostate cancer cells can be suppressed or the cancer can be reduced.
- an androgen receptor agonist especially non-steroidal androgen receptor agonists
- the ability of hormone resistance of prostate cancer cells to return to normal levels again. Prostate cancer growth began (tumor volume).
- cancer cells have normal hormone resistance to cancer cells [eg, LNCaP 104-S Cells (Cancer Res, 54, P1566-1573), LNCaP-FGC cells, etc.)) and orrogen receptor agonists (Especially non-steroidal androgen receptor agonists) or a salt thereof (if cancer cells have higher hormone resistance than normal cells [eg LNCaP 104-R2 cells (Cancer Res, 54, pl 566-1573), LNCaP -hr cells])
- cancer cells have higher hormone resistance than normal cells [eg LNCaP 104-R2 cells (Cancer Res, 54, pl 566-1573), LNCaP -hr cells])
- the timing of switching these administrations can be set as appropriate for each treatment, for example, 3 months to 5 years, preferably 6 months to 4 years, more preferably 1 year to 3 years, more preferably 1 year to 2 years It can be done in the range.
- MAB Maximum androgen blockade
- LHRH derivatives such as LHRH agonists
- lyase inhibitors such as lyase inhibitors
- aromatase inhibitors or antiandrogens for a certain period of time
- prostate cancer It is highly likely that hormone resistance has increased, and the androgen receptor agonist of the present invention (particularly, Non-steroidal androgen receptor agonists) or their salts are effective.
- the hormone resistance of cancer can be measured by measuring the reactivity of cancer cells to androgens, but can also be estimated by increasing or decreasing tumor markers, physiological indices, and tumor volume under certain drug administration.
- the NMR spectrum shows proton NMR, using tetramethylsilane as an internal standard.VAR I AN Gem ini — 200 (200 MHz spectrometer overnight), VAR I AN Mecurry-300 (300 MHz) Alternatively, it was measured with a JMTCO400Z54 (400 MHz) model of JEOL Ltd., and the 0 value was expressed in ppm.
- the infrared absorption spectrum was measured using Paragon 1000 manufactured by PerkinElmer.
- the specific rotation ([a] D ) was measured with a HIGH SENSITIVE POLAR I METER manufactured by Horiba or a DI P-370 polarimeter manufactured by JASCO.
- Methanesulfonyl chloride (3.77 mL) was added to a mixture of 5-methoxymethoxy-2-nitrobenzyl alcohol (8.65 g), triethylamine (8.48 mL), and tetrahydrofuran (130 mL) at 0 ° C. After stirring for 30 minutes, the mixture was concentrated, and acetone (150 mL) and sodium iodide (21.2 g) were added to the obtained residue. After stirring at room temperature for 1 hour, the mixture was concentrated, and the obtained residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried and concentrated.
- the obtained residue was subjected to silica gel column chromatography to obtain a pale yellow solid (10.8 g).
- a mixture of getyl malonate (8.00 g) and dimethyl sulfoxide (80 mL) was added sodium hydride (60% oily, 2.00 g) at room temperature, and the mixture was stirred for 20 minutes.
- the above pale yellow solid (10.8 g) was added, and the mixture was stirred for 5 minutes.
- the reaction was poured into water and extracted with ethyl acetate. Wash the extract with water and dry Dried and concentrated.
- the resulting residue was purified by silica gel column chromatography to obtain getyl 2- [5- (methoxymethoxy) 1-2-nitrobenzyl] malonate (10.4 g).
- Diisopropylamine (2.83 g) was dissolved in anhydrous ether (40 mL), and a 1.6 M n-butyllithium solution (15 mL) was added dropwise at ⁇ 60 ° C. while stirring and cooling. Then, 1-benzyl-5-methylpyrrolidin-12-one (3.78 g) was dissolved in anhydrous ether (15 mL), added dropwise at 160, dropped, and then returned to 5 ° C and stirred for 2 hours. The cooling bath was removed and dry carbon dioxide was introduced for 30 minutes. Ice water was added to the mixture, the aqueous layer was separated, and the organic layer was extracted twice with 2N-sodium hydroxide.
- Cis-1 (1-benzyl 5-methylpyrrolidine-3-yl) of methanol (350 mg), methyl alcohol (10 mL;), 1 N-hydrochloric acid (1.5 mL), 10% palladium on carbon (containing 300 mg of water) The mixture was stirred under a stream of hydrogen for 15 hours. The catalyst was removed by filtration, and the filtrate was concentrated to dryness to obtain cis- (5-methylpyrrolidine-3-yl) methanol hydrochloride (220 rag). 2003/010228
- Tetrahydrofuran (5.0 mL) was added to a 15% strength aqueous hexamethyldisilazide toluene solution (31 mL) under an argon atmosphere, and the mixture was cooled to -78 ° C. A mixture of 11-[(benzyloxy) carbonyl] -13-piperidinecarboxylate (4.00 g) and tetrahydrofuran (3.0 mL) was added, and the mixture was stirred for 20 minutes. A mixture of methane (1.3 mL) and tetrahydrofuran (2.0 mL) was added, and the temperature was raised to room temperature. After stirring for 12 hours, the reaction solution was poured into water and extracted with ethyl acetate.
- Lithium aluminum hydride (372 mg) was added at 0 ° C to a mixture of ethyl 3-ethyl-3-piperidinecarboxylate (1.68 g) and tetrahydrofuran (21 inL). The mixture was stirred for 3 hours while heating to room temperature. Water (0.37 mL), 25% aqueous hydroxide solution (0.37 mL), and water (1.10 mL) were sequentially added, and the mixture was stirred for 15 hours. The mother liquor was concentrated after filtering off insolubles using Celite to obtain 3- (hydroxymethyl) -3-methylpiperidine (1.01 g).
- Reference Example 30 A mixture of., 5- (benzyloxy) -1,2,3,4-tetrahydronaphthalene (6.30 g), dichloromethylmethyl ether (4.8 mL), and dichloromethane (50 mL) was added to a mixture of titanium tetrachloride (50 mL). A mixture of 7.3 mL) and dichloromethane (5.0 mL) was added dropwise at 0 at 30 minutes. After stirring, the reaction was poured into ice water and stirred vigorously for 30 minutes. The organic layer was washed with water, dried and concentrated.
- ⁇ -Dimethylthiocarbamoyl was added to a mixture of 2-bromo-1-fluorophenol (19.4 g), 1,8-diazapicyclo [2,2,2] octane (22.8 g) and 7 ⁇ -dimethylformamide (130 mL). Chloride (25.1 g) was added at room temperature for 30 minutes. After stirring for 4 hours, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, dried and concentrated, and the obtained solid was washed with methanol to obtain 0- (2-bromo-5-fluorophenyl) dimethylthiophenol (27.1 g).
- Lithium aluminum hydride (376 mg) was added at 0 ° C to a mixture of ethyl 4-ethyl-4-piperidinedicarboxylate (1.70 g) and tetrahydrofuran (22 mL), and the mixture was stirred for 4 hours.
- the insolubles were removed by filtration through Celite, and the mother liquor was concentrated to give (4-methyl-4-piberidinyl) methanol (1.28 g).
- Triethylamine (12.1 mL) and pyridine sulfur trioxide (13.8 g) were added to a mixture of BocD-prolinol (5.10 g) and dimethyl sulfoxide (35 mL).
- BocD-prolinol 5.10 g
- dimethyl sulfoxide 35 mL
- Reference example 90 Lithium aluminum hydride (160 mg) was added to a mixture of (2 S, 3 S) —2-methyl-1-[(1) —1-phenylethyl] pyrrolidine-1-carboxylate (1.04 g) and tetrahydrofuran (11 mL). ) was added at 0 ° C and stirred for 3 hours. Water (0.16 mL), 25% potassium hydroxide solution (0.16 mL) and water (0.48 mL) were sequentially added, and the mixture was stirred at room temperature for 16 hours.
- Tetrahydrofuran 13 mL was added to the residue obtained, and the resulting mixture was added to a mixture of lithium aluminum hydride (1.03 g) and tetrahydrofuran (35 mL) at room temperature for 15 minutes. After cooling to 0, water (1.0 mL), 25% potassium hydroxide solution (1.0 mL) and water (3.0 mL) were added sequentially, and the mixture was stirred at room temperature for 1.5 hours. The mother liquor was concentrated to give (2,3--3-hydroxy-12-methylpyrrolidine (1.19 g). This compound was used for the next reaction without further purification.
- Acetyl chloride (10.0 mL) was added to 2-phenylsuccinic acid (3.88 g), and the mixture was heated under reflux for 2 hours. After toluene was added to the reaction solution, the mixture was concentrated to dryness, dissolved in toluene (10 mL), benzylamine (2.2 g) was added, and the mixture was stirred at room temperature for 15 minutes. Then, acetyl chloride (10 mL) was added, and the mixture was heated under reflux for 2 hours. The reaction solution was concentrated, water was poured into the reaction product, and the mixture was extracted with ethyl acetate. The extract was washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 1-benzyl-3-phenylpyrrolidine-2,5-dione (4.1 g).
- Acetyl chloride (25 mL) was added to D-malic acid '(8 g), and the mixture was heated under reflux for 2.5 hours, concentrated to dryness, and toluene was added and concentrated to dryness twice.
- Toluene (25 ml) was added to the residue, benzylamine (6.7 g) was added dropwise with ice cooling and stirring, and the mixture was returned to room temperature and stirred for 30 minutes. Then, acetyl chloride (25 mL) was added, and the mixture was heated under reflux for 2.5 hours, concentrated and dried, and toluene was added and concentrated twice to dryness.
- the residue was purified by silica gel column chromatography 1 to obtain (3-3-acetoxy-1-benzyl-2,5-dioxopyrrolidine (14.9 g).
- Decant to separate the tetrahydrofuran layer add tetrahydrofuran (containing stabilizer) to the residue, repeat the decanting three times, combine and concentrate the tetrahydrofuran solution, add dichloromethane to the residue, extract twice, wash with saturated brine, and dry the extract. After drying over sodium sulfate, the mixture was concentrated to dryness.
- Basic residue Purification by silica gel column chromatography gave (2S, 3-1-benzyl-2-methylpyrrolidin-3-ol (10.1 g).
- Ethyl (diethoxyphosphoryl) acetate (3.54 g) was dissolved in anhydrous tetrahydrofuran (20 mL), sodium hydride (60% oily, 0.63 g) was added under ice-cooling and stirring, and the mixture was returned to room temperature and stirred for 10 minutes. . Then, tert-butyl 3-oxopyrrolidine-1-carboxylate (1.47 g) dissolved in anhydrous tetrahydrofuran (6 mL) was added under ice cooling and stirring, and the mixture was stirred at room temperature for 1.5 hours.
- tert-butyl 3_ (2-ethoxy-2-oxoethyl) pipa lidine-1-carboxylate (1.75 g).
- Acetic acid 70 mL was kept at 15 to 20 ° C, sodium borohydride (4.66 g) was added little by little, and the mixture was stirred at this temperature for 30 minutes. Then, acetonitrile (35 mL) was added, and the mixture was cooled to 5 ° C and stirred, and 2-methyl-1-[(1-1-phenylenyl) -4,5-dihydro-1 ⁇ pyrrolyl-3 was added.
- -Benzyl carboxylate (13.2 g) was dissolved in acetonitrile (35 mL) and added dropwise. The mixture was stirred for 3 hours while keeping it at 0.0 to 8. After the reaction solution was concentrated to dryness, the residue was washed with saturated sodium carbonate.
- Example 7 (Production of compound 7) 4 A mixture of monofluoro-1-naphthonitrile (100 mg), morpholine (0.10 mL), potassium carbonate (162 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100 for 3 hours. . After cooling to room temperature, the reaction was poured into water and extracted with ethyl acetate. The extract was washed with water, dried and concentrated. The resulting residue was purified by silica gel column chromatography to obtain 4- (4-morpholinyl) -11-naphthonitrile (113 mg) (Compound 7).
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03788076.2A EP1553074B1 (en) | 2002-08-12 | 2003-08-11 | Fused benzene derivative and use |
US10/524,452 US7649001B2 (en) | 2002-08-12 | 2003-08-11 | Fused benzene derivative and use |
MXPA05001631A MXPA05001631A (es) | 2002-08-12 | 2003-08-11 | Derivado de benceno fusionado y su uso. |
AU2003254993A AU2003254993A1 (en) | 2002-08-12 | 2003-08-11 | Fused benzene derivative and use |
NZ538713A NZ538713A (en) | 2002-08-12 | 2003-08-11 | Fused benzene derivative and use |
CA002495383A CA2495383A1 (en) | 2002-08-12 | 2003-08-11 | Fused benzene derivative and use |
BR0313405-9A BR0313405A (pt) | 2002-08-12 | 2003-08-11 | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
IL16678905A IL166789A0 (en) | 2002-08-12 | 2005-02-09 | Fused benzene derivative and use |
NO20051270A NO20051270L (no) | 2002-08-12 | 2005-03-11 | Sammensmeltet benzenderivat og anvendelse |
HK05112218.6A HK1080067A1 (zh) | 2002-08-12 | 2005-12-30 | 稠合苯衍生物及應用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002/235275 | 2002-08-12 | ||
JP2002235275 | 2002-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004016576A1 true WO2004016576A1 (ja) | 2004-02-26 |
Family
ID=31884376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010228 WO2004016576A1 (ja) | 2002-08-12 | 2003-08-11 | 縮合ベンゼン誘導体および用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US7649001B2 (ja) |
EP (1) | EP1553074B1 (ja) |
KR (1) | KR20050044902A (ja) |
CN (1) | CN1688527A (ja) |
AU (1) | AU2003254993A1 (ja) |
BR (1) | BR0313405A (ja) |
CA (1) | CA2495383A1 (ja) |
HK (1) | HK1080067A1 (ja) |
IL (1) | IL166789A0 (ja) |
MX (1) | MXPA05001631A (ja) |
NO (1) | NO20051270L (ja) |
NZ (1) | NZ538713A (ja) |
PL (1) | PL375042A1 (ja) |
WO (1) | WO2004016576A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005090282A1 (en) * | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
WO2005115361A2 (en) * | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
WO2007097289A1 (ja) * | 2006-02-20 | 2007-08-30 | Takeda Pharmaceutical Company Limited | 新規医薬 |
WO2008066117A1 (fr) | 2006-11-30 | 2008-06-05 | Takeda Pharmaceutical Company Limited | Composé amine cyclique |
WO2008153091A1 (ja) | 2007-06-13 | 2008-12-18 | Takeda Pharmaceutical Company Limited | スクリーニング方法 |
US7585877B2 (en) | 2005-01-10 | 2009-09-08 | Acadia Pharmaceuticals, Inc. | Aminophenyl derivatives as selective androgen receptor modulators |
WO2010104194A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
US7807691B2 (en) | 2005-05-13 | 2010-10-05 | Eli Lilly And Company | Substituted N-arylpyrrolidines as selective androgen receptor modulators |
US7834051B2 (en) | 2007-08-07 | 2010-11-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compounds |
US11512069B2 (en) | 2016-08-08 | 2022-11-29 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
US11629134B2 (en) | 2015-12-17 | 2023-04-18 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2463420T3 (es) * | 2002-11-01 | 2014-05-27 | Iris International, Inc. | Inmuno-PCR sándwich por desplazamiento |
US20070004679A1 (en) * | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
WO2006038119A1 (en) * | 2004-10-08 | 2006-04-13 | Warner-Lambert Company Llc | Stereoselective synthesis of n-protected alkoxy prolines |
EP2302078B1 (en) * | 2004-11-03 | 2015-07-15 | Iris Molecular Diagnostics, Inc. | Microbubbles for affinity concentration |
EP1842226B2 (en) * | 2004-11-03 | 2014-07-02 | Iris International, Inc. | Homogeneous analyte detection |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
US8592452B2 (en) * | 2005-08-01 | 2013-11-26 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
AU2009215799B2 (en) * | 2008-02-21 | 2013-08-22 | Iris International Inc. | Method for early determination of recurrence after therapy for prostate cancer |
ES2488990T3 (es) | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
US8268872B2 (en) * | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
PT2568806T (pt) | 2010-05-12 | 2016-08-05 | Radius Health Inc | Regimes terapêuticos |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
FI20116033A (fi) | 2011-10-18 | 2013-04-19 | Juha Pulkkinen | Uudet ei-steroidiset yhdisteet androgeenireseptorin muuntelijoina |
CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
EP4066827A1 (en) | 2016-06-22 | 2022-10-05 | Ellipses Pharma Ltd | Ar+ breast cancer treatment methods |
CA3070171A1 (en) * | 2017-07-18 | 2019-01-24 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
WO2024059951A1 (en) * | 2022-09-22 | 2024-03-28 | The University Of British Columbia | Inhibitors of the androgen receptor dna-binding domain |
CN115475158A (zh) * | 2022-09-27 | 2022-12-16 | 广西科技大学 | 一种萘腈类衍生物在制备抗肿瘤药物组合物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000617A2 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
WO2002050067A2 (en) * | 2000-12-20 | 2002-06-27 | Eli Lilly And Company | Pharmaceutical heterocyclic compounds |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK203990D0 (da) | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
DK148392D0 (da) | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
FR2712591B1 (fr) | 1993-11-19 | 1996-02-09 | Pf Medicament | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. |
US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
HUP0103761A3 (en) | 1998-10-08 | 2002-11-28 | Takeda Chemical Industries Ltd | Compositions for retarding change of hormone-dependent cancer into hormone-independent cancer and their use |
WO2001002392A1 (en) | 1999-06-30 | 2001-01-11 | Bristol-Myers Squibb Company | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
UA36514C2 (uk) * | 1999-12-28 | 2003-12-15 | Інститут Монокристалів Науково-Технологічного Концерну "Інститут Монокристалів" Нан України | Спосіб одержання похідних піразолінілнафталевої кислоти |
BR0111869A (pt) | 2000-06-28 | 2003-09-23 | Bristol Myers Squibb Co | Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear |
WO2002011209A2 (en) | 2000-08-01 | 2002-02-07 | Emagin Corporation | Method of patterning color changing media for organic light emitting diode display devices |
AU2001269943B2 (en) | 2000-09-19 | 2006-11-09 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
MXPA03011083A (es) | 2001-06-11 | 2004-07-08 | Biovitrum Ab | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. |
WO2003006455A1 (en) | 2001-07-11 | 2003-01-23 | Eli Lilly And Company | Pharmaceutical compounds with serotonin receptor activity |
DE60239207D1 (de) | 2001-08-10 | 2011-03-31 | Takeda Pharmaceutical | Gnrh-agonistische kombinationsmittel |
WO2003057669A1 (fr) | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Antagonistes du recepteur androgene |
US20050159361A1 (en) | 2002-03-11 | 2005-07-21 | Takahito Hara | Remedies for sex hormone-dependent disease |
JP4447826B2 (ja) | 2002-06-03 | 2010-04-07 | 武田薬品工業株式会社 | 変異アンドロゲン受容体、それを発現する癌細胞、それらの作出方法およびそれらの用途 |
US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
US7709516B2 (en) * | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
-
2003
- 2003-08-11 MX MXPA05001631A patent/MXPA05001631A/es not_active Application Discontinuation
- 2003-08-11 KR KR1020057002416A patent/KR20050044902A/ko not_active Application Discontinuation
- 2003-08-11 US US10/524,452 patent/US7649001B2/en not_active Expired - Fee Related
- 2003-08-11 CA CA002495383A patent/CA2495383A1/en not_active Abandoned
- 2003-08-11 NZ NZ538713A patent/NZ538713A/en unknown
- 2003-08-11 WO PCT/JP2003/010228 patent/WO2004016576A1/ja not_active Application Discontinuation
- 2003-08-11 EP EP03788076.2A patent/EP1553074B1/en not_active Expired - Lifetime
- 2003-08-11 PL PL03375042A patent/PL375042A1/xx not_active Application Discontinuation
- 2003-08-11 CN CNA038241315A patent/CN1688527A/zh active Pending
- 2003-08-11 BR BR0313405-9A patent/BR0313405A/pt not_active IP Right Cessation
- 2003-08-11 AU AU2003254993A patent/AU2003254993A1/en not_active Abandoned
-
2005
- 2005-02-09 IL IL16678905A patent/IL166789A0/xx unknown
- 2005-03-11 NO NO20051270A patent/NO20051270L/no not_active Application Discontinuation
- 2005-12-30 HK HK05112218.6A patent/HK1080067A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000617A2 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
WO2002050067A2 (en) * | 2000-12-20 | 2002-06-27 | Eli Lilly And Company | Pharmaceutical heterocyclic compounds |
Non-Patent Citations (3)
Title |
---|
KARVONEN ULLA ET AL.: "Interaction of androgen receptors with androgen response element in intact cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 25, 1997, pages 15973 - 15979, XP002931882 * |
See also references of EP1553074A4 * |
VAN DORT MARCIAN E., ROBINS DIANE M., WAYBURN BESS: "Design, synthesis and pharmacological characterization of 4-(4,4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl)-2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 17, 2000, pages 3344 - 3347, XP002973524 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005090282A1 (en) * | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US9359285B2 (en) | 2004-03-12 | 2016-06-07 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8865918B2 (en) | 2004-03-12 | 2014-10-21 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
WO2005115361A2 (en) * | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
WO2005115361A3 (en) * | 2004-05-17 | 2006-03-16 | Acadia Pharm Inc | Androgen receptor modulators and method of treating disease using the same |
US7268232B2 (en) | 2004-05-17 | 2007-09-11 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
JP2007538085A (ja) * | 2004-05-17 | 2007-12-27 | アカディア ファーマシューティカルズ インコーポレイティド | アンドロゲン受容体モジュレーターおよびそれを用いて疾患を治療する方法 |
US7585877B2 (en) | 2005-01-10 | 2009-09-08 | Acadia Pharmaceuticals, Inc. | Aminophenyl derivatives as selective androgen receptor modulators |
US7807691B2 (en) | 2005-05-13 | 2010-10-05 | Eli Lilly And Company | Substituted N-arylpyrrolidines as selective androgen receptor modulators |
WO2007097289A1 (ja) * | 2006-02-20 | 2007-08-30 | Takeda Pharmaceutical Company Limited | 新規医薬 |
US8013008B2 (en) | 2006-11-30 | 2011-09-06 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
WO2008066117A1 (fr) | 2006-11-30 | 2008-06-05 | Takeda Pharmaceutical Company Limited | Composé amine cyclique |
WO2008153091A1 (ja) | 2007-06-13 | 2008-12-18 | Takeda Pharmaceutical Company Limited | スクリーニング方法 |
US7834051B2 (en) | 2007-08-07 | 2010-11-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compounds |
US8420694B2 (en) | 2007-08-07 | 2013-04-16 | Takeda Pharmaceutical Company Limited | Pyrrolidin-2-one derivatives as androgen receptor modulator |
WO2010104194A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
EP2781513A1 (en) | 2009-03-10 | 2014-09-24 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
US11629134B2 (en) | 2015-12-17 | 2023-04-18 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
US11512069B2 (en) | 2016-08-08 | 2022-11-29 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
IL166789A0 (en) | 2006-01-15 |
EP1553074B1 (en) | 2014-06-18 |
EP1553074A4 (en) | 2005-10-12 |
EP1553074A1 (en) | 2005-07-13 |
BR0313405A (pt) | 2005-07-12 |
HK1080067A1 (zh) | 2006-04-21 |
PL375042A1 (en) | 2005-11-14 |
AU2003254993A1 (en) | 2004-03-03 |
CA2495383A1 (en) | 2004-02-26 |
NO20051270L (no) | 2005-05-09 |
CN1688527A (zh) | 2005-10-26 |
NZ538713A (en) | 2007-01-26 |
KR20050044902A (ko) | 2005-05-13 |
US7649001B2 (en) | 2010-01-19 |
MXPA05001631A (es) | 2005-08-19 |
US20060106067A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004016576A1 (ja) | 縮合ベンゼン誘導体および用途 | |
JP5070054B2 (ja) | 環状アミン化合物 | |
JP5292390B2 (ja) | アンドロゲン受容体調節剤としてのピロリジン−2−オン誘導体 | |
WO2009133861A1 (ja) | 環状アミン化合物 | |
JP2023159166A (ja) | 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法 | |
CA3038979A1 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
CN111454248A (zh) | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 | |
JPWO2007097289A1 (ja) | 新規医薬 | |
WO2008047831A1 (fr) | Inhibiteurs de JAK | |
JP2015505321A (ja) | イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド | |
IL302137A (en) | Compounds and methods for targeted degradation of androgen receptor protein | |
CA2615209A1 (en) | Mc4r-ag0nists for the treatment of urinary tract dysfunction | |
UA126997C2 (uk) | Галоаліламінові сполуки та їх застосування | |
EP2597095A1 (en) | Fused heterocyclic compound and application thereof | |
JP5241507B2 (ja) | 環状アミン化合物 | |
JP4426792B2 (ja) | 縮合ベンゼン誘導体および用途 | |
KR20170095243A (ko) | Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체 | |
WO2005021555A1 (ja) | 二環性ピペラジン化合物およびその用途 | |
CN117337280A (zh) | 作为Kv1.3钾SHAKER通道阻断剂的芳基杂环化合物 | |
JP2005035935A (ja) | オキサゾール化合物およびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 166789 Country of ref document: IL Ref document number: 375042 Country of ref document: PL Ref document number: 2003788076 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2495383 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001631 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057002416 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003254993 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538713 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038241315 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002416 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003788076 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006106067 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10524452 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500293 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10524452 Country of ref document: US |